Genomic Variants Driven Drug Repurposing for Tuberculosis by Utilizing Established Bioinformatic Based Approach

BBREP-D-22-00414R1 /BBREP-D-22-00414





Decision on submission to Biochem | Universitas Ahmad Dahlan Yogya | Contact - Journal Article Publishi | Re: The article transfered from an

mail.google.com/mail/u/0/?ik=d44992c450&view=pt&search=all&permthid=thread-f%3A1741845805366117068&simpl=msg-f%3A1741845805366117...

Decision on submission to Biochemistry and Biophysics Reports
1 message

Biochemistry and Biophysics Reports <em@editorialmanager.com>
Reply-To: Biochemistry and Biophysics Reports <support@elsevier.com>
To: Lalu Muhammad Irham <lalu.irham@pharm.uad.ac.id>

You are being carbon copied ("cc:d") on an e-mail "To" "Dyah A Perwitasari" dyah.perwitasari@pharm.uad.ac.id
CC: "Lalu Muhammad Irham" lalu.irham@pharm.uad.ac.id, "Wirawan Adikusuma" adikusuma28@gmail.com

Manuscript Number: BBREP-D-22-00414R1

Genomic Variants Driven Drug Repurposing for Tuberculosis by Utilizing Established Bioinformatic Based Approach

Dear Prof Perwitasari,

Thank you for submitting your manuscript to Biochemistry and Biophysics Reports.

I am pleased to inform you that your manuscript has been accepted for publication.

My comments, and any reviewer comments, are below.
Your accepted manuscript will now be transferred to our production department. We will create a proof which you will be asked to check, and you will also be asked to complete a number of online forms required for publication. If we need additional information from you during the production process, we will contact you directly.

We appreciate you submitting your manuscript to Biochemistry and Biophysics Reports and hope you will consider us again for future submissions.

Kind regards,
Cornelis p Tensen
Executive Editor

Biochemistry and Biophysics Reports

Editor and Reviewer comments:

Reviewer #1: General: Thank you very much for your efforts in revising the manuscript based on the reviewer's suggestions.

Special comment:
1. Please include the number of the bar chart (Figure 2B).

More information and support

Eligible for a waiver?

If your manuscript was transferred from another journal and submitted before 31 December 2022 to this open access journal, you do not have to pay the article publishing charge (APC). We will waive the APC.

How to get your APC waived?

Please use this webform to contact our support team: https://service.elsevier.com/app/contact/supporthub/publishing/

You can then expect the following:

1. You will receive a voucher code upon successful validation.
2. You will receive an email with a link to the Rights and Access form.
3. Enter the voucher code in the Rights and Access form, in the Publishing options step and complete the form.

Important note:

Please complete the Rights and Access Form within 14 days of receipt of the link to the form. An open access invoice will be sent to you if you don't complete the Rights and Access form.

FAQ: When and how will I receive the proofs of my article?
https://service.elsevier.com/app/answers/detail/a_id/6007/p/10592/supporthub/publishing/related/

You will find information relevant for you as an author on Elsevier's Author Hub: https://www.elsevier.com/authors

FAQ: How can I reset a forgotten password?
https://service.elsevier.com/app/answers/detail/a_id/28452/supporthub/publishing/
For further assistance, please visit our customer service site: https://service.elsevier.com/app/home/supporthub/publishing/
Here you can search for solutions on a range of topics, find answers to frequently asked questions, and learn more about Editorial Manager via interactive tutorials. You can also talk 24/7 to our customer support team by phone and 24/7 by live chat and email

#AU_BBREP#

To ensure this email reaches the intended recipient, please do not delete the above code

In compliance with data protection regulations, you may request that we remove your personal registration details at any time. (Use the following URL: https://www.editorialmanager.com/bbrep/login.asp?a=r). Please contact the publication office if you have any questions.

UNIVERSITAS
AHMAD DAHLAN

LALU MUHAMMAD IRHAM <lalu.irham@pharm.uad.ac.id>

Fwd: Decision on submission to Biochemistry and Biophysics Reports

2 messages

Dyah Perwitasari <dyah.perwitasari@pharm.uad.ac.id> Tue, Jul 26, 2022 at 2:00 PM
To: LALU MUHAMMAD IRHAM <lalu.irham@pharm.uad.ac.id>

---------- Forwarded message ---------
From: **Biochemistry and Biophysics Reports** <em@editorialmanager.com>
Date: Mon, Jul 25, 2022, 21:32
Subject: Decision on submission to Biochemistry and Biophysics Reports
To: Dyah A Perwitasari <dyah.perwitasari@pharm.uad.ac.id>

Manuscript Number: BBREP-D-22-00414

Genomic Variants Driven Drug Repurposing for Tuberculosis by Utilizing Established Bioinformatic Based Approach

Dear Prof Perwitasari,

Thank you for submitting your manuscript to Biochemistry and Biophysics Reports.

I have completed my evaluation of your manuscript. The reviewers recommend reconsideration of your manuscript following minor revision and modification. I invite you to resubmit your manuscript after addressing the comments below. Please resubmit your revised manuscript by Aug 14, 2022.

When revising your manuscript, please consider all issues mentioned in the reviewers' comments carefully: please outline every change made in response to their comments and provide suitable rebuttals for any comments not addressed. Please note that your revised submission may need to be re-reviewed.

To submit your revised manuscript, please log in as an author at https://www.editorialmanager.com/bbrep/, and navigate to the "Submissions Needing Revision" folder under the Author Main Menu.

Biochemistry and Biophysics Reports values your contribution and I look forward to receiving your revised manuscript.

Kind regards,

Cornelis p Tensen

Executive Editor

Biochemistry and Biophysics Reports

Editor and Reviewer comments:

In its current state, the level of English throughout your manuscript does not meet the journal's required standard. You may wish to ask a native speaker to check your manuscript for grammar, style and syntax, or use the professional language editing options available from Elsevier Author Services: https://webshop.elsevier.com/

Reviewer #1: The title and topic will be of interest to the readers of the journal, however a revision should be addressed on a few points as stated below

Specific comments:
1. Please consider using an English editing service for grammatical correction.
2. Consider firstly mentioning all abbreviations at the beginning of writing.
3. Some sentences in the method and results section are redundant.
4. The limitation does not present only the limitations of the manuscript. I found this section poor because solutions (further research or implications) were not discussed to overcome possible limitations.
5. It is still unclear whether this will be applied to combat TB drug resistance or prevent the adverse events of TB drugs.

Additional comments: This manuscript is largely descriptive but provides interesting insights on drug repurposing and strategies to approach this topic. However, English must be improved before acceptance. Resolution of most images is poor and need to be fixed. Figure legends are poorly described.

Submitting Your Revision:

Regardless of the file format of your original submission, at revision we expect you to provide us with article files following the instruction below:

* Do not submit any prior version of your manuscript - only the most recent revised version.

* Manuscript file, tables, and figure captions must be in an editable format (i.e., MS Word or LaTeX).

* Figures files should be correctly labeled and uploaded as separate files in one of the following formats: TIF, JPG or EPS.

* If figures are "embedded" in the manuscript file, they should be placed next to the relevant text in the manuscript and provided also as separate files. The corresponding caption should be placed directly below the figure or table.

Please refer to the online Guide for Authors (https://www.elsevier.com/journals/biochemistry-and-biophysics-reports/2405-5808/guide-for-authors) for additional information on preparing your revision and formatting requirements. You can contact the journal at support@elsevier.com if you have any specific questions.

More information and support

FAQ: How do I revise my submission in Editorial Manager?

https://service.elsevier.com/app/answers/detail/a_id/28463/supporthub/publishing/

You will find information relevant for you as an author on Elsevier's Author Hub: https://www.elsevier.com/authors

FAQ: How can I reset a forgotten password?
https://service.elsevier.com/app/answers/detail/a_id/28452/supporthub/publishing/
For further assistance, please visit our customer service site: https://service.elsevier.com/app/home/supporthub/publishing/
Here you can search for solutions on a range of topics, find answers to frequently asked questions, and learn more about Editorial Manager via interactive tutorials. You can also talk 24/7 to our customer support team by phone and 24/7 by live chat and email

#AU_BBREP#

To ensure this email reaches the intended recipient, please do not delete the above code

---

UNIVERSITAS AHMAD DAHLAN

Kampus 1: *Jln. Kapas No. 9 Yogyakarta*

Kampus 2: *Jl. Pramuka 42, Sidikan, Umbulharjo, Yogyakarta 55161*

Kampus 3: *Jl. Prof. Dr. Soepomo, S.H., Janturan, Warungboto, Umbulharjo, Yogyakarta 55164*

Kampus 4: *Jl.Ringroad Selatan, Yogyakarta*

Kampus 5: *Jl. Ki Ageng Pemanahan 19, Yogyakarta*

Kontak

Fwd: Send Back to Author: Request to Edit Submission

1 message

Dyah Perwitasari <dyah.perwitasari@pharm.uad.ac.id> Mon, Aug 8, 2022 at 7:05 PM
To: LALU MUHAMMAD IRHAM <lalu.irham@pharm.uad.ac.id>

---------- Forwarded message ---------
From: **Cristina Monterrubio-Martin** <em@editorialmanager.com>
Date: Mon, Aug 8, 2022, 14:01
Subject: Send Back to Author: Request to Edit Submission
To: Dyah A Perwitasari <dyah.perwitasari@pharm.uad.ac.id>

Article Title: Genomic Variants Driven Drug Repurposing for Tuberculosis by Utilizing Established Bioinformatic Based Approach
Corresponding Author: Prof Dyah A Perwitasari

Dear Prof Perwitasari,

Thank you for resubmitting your submission entitled "Genomic Variants Driven Drug Repurposing for Tuberculosis by Utilizing Established Bioinformatic Based Approach" has been received by Biochemistry and Biophysics Reports. However, before we can continue with the review process we ask you to address the following:

Your submission is missing a Highlights section. Highlights are mandatory for this journal as they help increase the discoverability of your article via search engines. They consist of 3 to 5 bullet points (no figures, maximum 85 characters, including spaces, per bullet point) that capture the novel results of your research as well as new methods that were used during the study (if any).

Please log onto Elsevier Editorial System as an Author:

https://www.editorialmanager.com/bbrep/.
1. Go to the menu item "Submissions/Revisions Sent Back to Author".
2. Click "Edit Submission/Revision".
3. Click on the relevant submission step on the left-hand menu.
4. Provide or modify the item/information as requested.
5. Go to "Attach Files" and "Build PDF for my Approval".
6. View and Approve your new PDF file including the changed item(s), or if needed, Edit again.

Thank you for submitting your work to the journal, and if you have any questions, please do not hesitate to contact me.
Yours sincerely,

Biochemistry and Biophysics Reports

Have questions or need assistance?
For further assistance, please visit our customer service site: http://help.elsevier.com/app/answers/list/p/9435/. Here you can search for solutions on a range of topics, find answers to frequently asked questions, and learn more about Editorial Manager via interactive tutorials. You can also talk 24/5 to our customer support team by phone and 24/7 by live chat and email.

#AU_BBREP#

To ensure this email reaches the intended recipient, please do not delete the above code

---

Fwd: Confirming handling editor for submission to Biochemistry and Biophysics Reports

1 message

Dyah Perwitasari <dyah.perwitasari@pharm.uad.ac.id> Thu, Jul 21, 2022 at 4:55 PM
To: LALU MUHAMMAD IRHAM <lalu.irham@pharm.uad.ac.id>

---------- Forwarded message ---------
From: **Biochemistry and Biophysics Reports** <em@editorialmanager.com>
Date: Thu, Jul 21, 2022, 10:15
Subject: Confirming handling editor for submission to Biochemistry and Biophysics Reports
To: Dyah A Perwitasari <dyah.perwitasari@pharm.uad.ac.id>

This is an automated message.

Manuscript Number: BBREP-D-22-00414

Genomic Variants Driven Drug Repurposing for Tuberculosis by Utilizing Established Bioinformatic Based Approach

Dear Prof Perwitasari,

The above referenced manuscript will be handled by Managing Editor Ph.D Cristina Monterrubio-Martin.

To track the status of your manuscript, please log into Editorial Manager at https://www.editorialmanager.com/bbrep/.

Thank you for submitting your work to this journal.

Kind regards,

Biochemistry and Biophysics Reports

More information and support

You will find information relevant for you as an author on Elsevier's Author Hub: https://www.elsevier.com/authors

FAQ: How can I reset a forgotten password?
https://service.elsevier.com/app/answers/detail/a_id/28452/supporthub/publishing/
For further assistance, please visit our customer service site: https://service.elsevier.com/app/home/supporthub/publishing/
Here you can search for solutions on a range of topics, find answers to frequently asked questions, and learn more about Editorial Manager via interactive tutorials. You can also talk 24/7 to our customer support team by phone and 24/7 by live chat and email

#AU_BBREP#

To ensure this email reaches the intended recipient, please do not delete the above code

UNIVERSITAS AHMAD DAHLAN

Kampus 1: *Jln. Kapas No. 9 Yogyakarta*

Kampus 2: *Jl. Pramuka 42, Sidikan, Umbulharjo, Yogyakarta 55161*

Kampus 3: *Jl. Prof. Dr. Soepomo, S.H., Janturan, Warungboto, Umbulharjo, Yogyakarta 55164*

FW: BBRC-22-3476: Decision

1 message

dyah.perwitasari@pharm.uad.ac.id <dyah.perwitasari@pharm.uad.ac.id> Wed, Jul 20, 2022 at 8:10 AM
To: LALU MUHAMMAD IRHAM <lalu.irham@pharm.uad.ac.id>

Meniko

Prof.Dr.apt.Dyah Aryani Perwitasari., M.Si., Ph.D

Fakultas Farmasi

Faculty of Pharmacy

Universitas Ahmad Dahlan

Yogyakarta

From: BBRC (ELS)
Sent: Tuesday, July 19, 2022 9:56 AM
To: Dyah A Perwitasari
Subject: BBRC-22-3476: Decision

Your Submission BBRC-22-3476

Dear Prof Perwitasari,

Thank you for your interest and submission to Biochemical and Biophysical Research Communications. Unfortunately, after an initial evaluation, I feel your manuscript is not appropriate for the readership of this journal. **Your manuscript presents some potentially useful bioinformatics analyses, but without sufficient experimental characterization of biological functions of the proposed targets of interest the amount of new mechanistic insight at this stage of the work does not warrant selection for rapid advance publication in this journal.**

I do, however, think your paper could be considered by the journal Biochemistry and Biophysics Reports (BB Reports). I would like to suggest that you take advantage of our article transfer service which gives you the option to have your manuscript files and details transferred. This removes the need for you to resubmit and reformat your manuscript, saving you valuable time and effort during the submission process.

BB Reports is an open access, online only, peer-reviewed international journal which publishes original research in all aspects of Biochemistry, Biophysics and related areas like Molecular and Cell Biology.

- All content published in the journal is indexed in PubMed Central, Scopus and the DOAJ, as well as in the Emerging Sources Citation Index, so accepted papers will appear in the Web of Science.
- If you do choose to transfer your paper to BBREPs, please identify your submission as a 'short communication' on transfer and we will ensure that peer review process is expedited
- The primary criteria for acceptance are that the work is original, scientifically and technically sound and provides valuable knowledge to life sciences research.

Please confirm by Aug 18 2022 11:59PM whether you would like to accept this transfer offer:

To accept the transfer offer and select your preferred journal, please click: Agree to Transfer
Please note that you may need to log in to the BB Reports manuscript submission portal in order to finalise your transfer.

To decline the transfer offer, please click: Decline to Transfer

We appreciate you submitting your manuscript to Biochemical and Biophysical Research Communications and thank you for giving us the opportunity to consider your work.

Kind regards,

Cristina Monterrubio-Martin, Ph.D
Managing Editor
Biochemical and Biophysical Research Communications

Additional comments:

More information and support

You will find more information about Elsevier's Article Transfer Service here: www.elsevier.com/authors/article-transfer-service.

Please note that your acceptance of a transfer offer does not guarantee that your paper will be published in the journal you have selected.

You will find information relevant for you as an author on Elsevier's Author Hub: https://www.elsevier.com/authors

FAQ: How can I reset a forgotten password?
https://service.elsevier.com/app/answers/detail/a_id/28452/supporthub/publishing/
For further assistance, please visit our customer service site: https://service.elsevier.com/app/home/supporthub/publishing/
Here you can search for solutions on a range of topics, find answers to frequently asked questions, and learn more about Editorial Manager via interactive tutorials. You can also talk 24/7 to our customer support team by phone and 24/7 by live chat and email

#AU_BBRC#

To ensure this email reaches the intended recipient, please do not delete the above code

---

UNIVERSITAS AHMAD DAHLAN

Kampus 1: *Jln. Kapas No. 9 Yogyakarta*

Kampus 2: *Jl. Pramuka 42, Sidikan, Umbulharjo, Yogyakarta 55161*

Kampus 3: *Jl. Prof. Dr. Soepomo, S.H., Janturan, Warungboto, Umbulharjo, Yogyakarta 55164*

Kampus 4: *Jl.Ringroad Selatan, Yogyakarta*

Kampus 5: *Jl. Ki Ageng Pemanahan 19, Yogyakarta*

View Letter - Google Chrome

editorialmanager.com/bbrep/ViewLetter.aspx?id=172675&lsid={FB84C712-F46B-4761-9644-E9AF9C59FA6C}

View Letter

Close

Date: Aug 22, 2022
To: "Dyah A Perwitasari" dyah.perwitasari@pharm.uad.ac.id
cc: "Lalu Muhammad Irham" lalu.irham@pharm.uad.ac.id, "Wirawan Adikusuma" adikusuma28@gmail.com
From: "Biochemistry and Biophysics Reports" support@elsevier.com
Subject: Decision on submission to Biochemistry and Biophysics Reports

Manuscript Number: BBREP-D-22-00414R1

Genomic Variants Driven Drug Repurposing for Tuberculosis by Utilizing Established Bioinformatic Based Approach

Dear Prof Perwitasari,

Thank you for submitting your manuscript to Biochemistry and Biophysics Reports.

I am pleased to inform you that your manuscript has been accepted for publication.

My comments, and any reviewer comments, are below.
Your accepted manuscript will now be transferred to our production department. We will create a proof which you will be asked to check, and you will also be asked to complete a number of online forms required for publication. If we need additional information from you during the production process, we will contact you directly.

We appreciate you submitting your manuscript to Biochemistry and Biophysics Reports and hope you will consider us again for future submissions.

Kind regards,
Cornelis p Tensen
Executive Editor

Biochemistry and Biophysics Reports

Editor and Reviewer comments:

Reviewer #1: General: Thank you very much for your efforts in revising the manuscript based on the reviewer's suggestions.

Special comment:
1. Please include the number of the bar chart (Figure 2B).

More information and support

Eligible for a waiver?

If your manuscript was transferred from another journal and submitted before 31 December 2022 to this open access journal, you do not have to pay the article publishing charge (APC). We will waive the APC.

How to get your APC waived?

Please use this webform to contact our support team: https://service.elsevier.com/app/contact/supporthub/publishing/


editorialmanager.com/bbrep/default1.aspx
Biochemistry and Biophysics Reports
Editorial Manager
HOME • LOGOUT • HELP • REGISTER • UPDATE MY INFORMATION • JOURNAL OVERVIEW
MAIN MENU • CONTACT US • SUBMIT A MANUSCRIPT • INSTRUCTIONS FOR AUTHORS • POLICIES
Role: Author
Username: dperwitasari
Submissions with an Editorial Office Decision for Author
Page: 1 of 1 (1 total completed submissions)
Results per page 10
Action
Manuscript Number
Title
Initial Date Submitted
Status Date
Current Status
Date Final Disposition Set
Final Disposition
Action Links
BBREP-D-22-00414
Genomic Variants Driven Drug Repurposing for Tuberculosis by Utilizing Established Bioinformatic Based Approach
Jul 21, 2022
Aug 22, 2022
Completed - Accept
Aug 22, 2022
Accept
Page: 1 of 1 (1 total completed submissions)
Results per page 10

Manuscript Number: BBREP-D-22-00414

Genomic Variants Driven Drug Repurposing for Tuberculosis by Utilizing Established Bioinformatic Based Approach

Dear Prof Perwitasari,

Thank you for submitting your manuscript to Biochemistry and Biophysics Reports.

I have completed my evaluation of your manuscript. The reviewers recommend reconsideration of your manuscript following minor revision and modification. I invite you to resubmit your manuscript after addressing the comments below. Please resubmit your revised manuscript by Aug 14, 2022.

When revising your manuscript, please consider all issues mentioned in the reviewers' comments carefully: please outline every change made in response to their comments and provide suitable rebuttals for any comments not addressed. Please note that your revised submission may need to be re-reviewed.

To submit your revised manuscript, please log in as an author at https://www.editorialmanager.com/bbrep/, and navigate to the "Submissions Needing Revision" folder under the Author Main Menu.

Biochemistry and Biophysics Reports values your contribution and I look forward to receiving your revised manuscript.

Kind regards,

Cornelis p Tensen

Executive Editor

Biochemistry and Biophysics Reports

Editor and Reviewer comments:

In its current state, the level of English throughout your manuscript does not meet the journal’s required standard. You may wish to ask a native speaker to check your manuscript for grammar, style and syntax, or use the professional language editing options available from Elsevier Author Services: https://webshop.elsevier.com/

Reviewer #1: The title and topic will be of interest to the readers of the journal, however a revision should be addressed on a few points as stated below

Specific comments:

1. Please consider using an English editing service for grammatical correction.
2. Consider firstly mentioning all abbreviations at the beginning of writing.
3. Some sentences in the method and results section are redundant.
4. The limitation does not present only the limitations of the manuscript. I found

this section poor because solutions (further research or implications) were not discussed to overcome possible limitations.
5. It is still unclear whether this will be applied to combat TB drug resistance or prevent the adverse events of TB drugs.

Additional comments: This manuscript is largely descriptive but provides interesting insights on drug repurposing and strategies to approach this topic. However, English must be improved before acceptance. Resolution of most images is poor and need to be fixed. Figure legends are poorly described.

Submitting Your Revision:

Regardless of the file format of your original submission, at revision we expect you to provide us with article files following the instruction below:

* Do not submit any prior version of your manuscript - only the most recent revised version.

* Manuscript file, tables, and figure captions must be in an editable format (i.e., MS Word or LaTeX).

* Figures files should be correctly labeled and uploaded as separate files in one of the following formats: TIF, JPG or EPS.

* If figures are "embedded" in the manuscript file, they should be placed next to the relevant text in the manuscript and provided also as separate files. The corresponding caption should be placed directly below the figure or table.

Please refer to the online Guide for Authors (https://www.elsevier.com/journals/biochemistry-and-biophysics-reports/2405-5808/guide-for-authors) for additional information on preparing your revision and formatting requirements. You can contact the journal at support@elsevier.com if you have any specific questions.

More information and support

FAQ: How do I revise my submission in Editorial Manager?

https://service.elsevier.com/app/answers/detail/a_id/28463/supporthub/publishing/

You will find information relevant for you as an author on Elsevier's Author Hub: https://www.elsevier.com/authors

FAQ: How can I reset a forgotten password?
https://service.elsevier.com/app/answers/detail/a_id/28452/supporthub/publishing/
For further assistance, please visit our customer service

site: https://service.elsevier.com/app/home/supporthub/publishing/
Here you can search for solutions on a range of topics, find answers to frequently asked questions, and learn more about Editorial Manager via interactive tutorials. You can also talk 24/7 to our customer support team by phone and 24/7 by live chat and email

#AU_BBREP#

To ensure this email reaches the intended recipient, please do not delete the above code

Biochemistry and Biophysics Reports

Genomic Variants Driven Drug Repurposing for Tuberculosis by Utilizing Established Bioinformatic Based Approach

--Manuscript Draft--

Manuscript Number:	BBREP-D-22-00414R1
Article Type:	Short Communication
Keywords:	Bioinformatics; drug repurposing; Drug discovery; Genomic variants; tuberculosis
Corresponding Author:	Dyah A Perwitasari, Ph.D Universitas Ahmad Dahlan Yogyakarta, Daerah Istimewa Yogyakart INDONESIA
First Author:	Lalu Muhammad Irham, Ph.D
Order of Authors:	Lalu Muhammad Irham, Ph.D
	Wirawan Adikusuma, Ph.D
	Dyah Aryani Perwitasari
Abstract:	A major challenge for translating the genomic of Tuberculosis (TB) into clinical implementation is to integrate the disease-associated variants and facilitate drug discovery through the concept of genomic-driven drug repurposing. Here, we utilized two established genomic databases, including a genome-wide association study (GWAS) and Phenome wide association study (PheWAS) to identify the genomic variants associated TB disease and further utilize them for drug target genes. By evaluating 3.425 of genomic variants associated TB disease which were overlapped with 200 TB associated genes. To prioritize the biological TB risk genes, we devised an in-silico pipeline as well as leveraging an established bioinformatics method based on six functional annotations (missense mutation, cis-eQTL, biological process, cellular component, molecular function, and KEGG molecular pathway analysis). Interestingly, based on the six functional annotations that we applied, finally we discovered 14 biological TB risk genes that might be very important related to the deregulation of the biological TB risk genes. Hence, we demonstrate that 12 drug target genes overlapped with 40 drugs for other indications and further suggest that may be repurposed for the treatment of TB. We highlighted that CD44, CCR5, CXCR4, and C3 are highly proposed promising TB targets since they are connected to SELP and HLA-B, which are biological TB risk genes with high systemic scores on functional annotations. In sum, the current study sheds light on the genomic variants involved in TB pathogenesis as the biological TB risk genes and empirical evidence that the genomics of TB may contribute to drug discovery.
Suggested Reviewers:	Eko Mugyanto Muhammadiyah University of Pekajangan Pekalongan giyan77@gmail.com Expert in Field of Drug repurposing
	Made Sarasmita Taipei Medical University arysarasmita@unud.ac.id Expert in field of Tuberculosis
Response to Reviewers:	

August 07, 2022

Dear Editors,

Please find our attached manuscript entitled "Genomic-Variants Driven Drug Repurposing for Tuberculosis by Utilizing Established Bioinformatic-Based Approach," which we are submitting for consideration for publication as an Original Research article in ***Biochemistry and Biophysics Reports*** (**BBREP-D-22-00414**). We are thankful for your insightful suggestions regarding our manuscript. Here, we are attaching the revised manuscript in accordance with the comments given by the reviewer. We have read through all the reviewers' suggestions very carefully, and made the necessary revisions based on these comments, as detailed below in a point-by-point format. The revised sections are highlighted in yellow. Finally, we would like to thank you once again for giving us the opportunity to improve our manuscript. We very much hope that these revisions are adequate. We appreciate your assistance and look forward to hearing from you.

Sincerely yours,

Prof. Dr apt Dyah Aryani Perwitasari M.Sc Ph.D

Dean of Faculty of Pharmacy,
Universitas Ahmad Dahlan, Yogyakarta, Indonesia
Jl. Prof. DR. Soepomo SH, Warungboto,
Kec. Umbulharjo, Kota Yogyakarta, Daerah Istimewa Yogyakarta

Research article

Genomic Variants-Driven Drug Repurposing for Tuberculosis by Utilizing the Established Bioinformatic-Based Approach

Lalu Muhammad Irham[1]., Wirawan Adikusuma[2]., Dyah Aryani Perwitasari[1]*

[1]*Faculty of Pharmacy, Universitas Ahmad Dahlan, Yogyakarta, Indonesia*

[2]*Departement of Pharmacy, University of Muhammadiyah Mataram, Mataram, Indonesia.*

***Correspondence:** Dyah Aryani Perwitasari; email:*dyah.perwitasari@pharm.uad.ac.id*

Abstract

A major challenge in translating genomic variants of Tuberculosis (TB) into clinical implementation is to integrate the disease-associated variants and facilitate drug discovery through the concept of genomic-driven drug repurposing. Here, we utilized two established genomic databases, namely a Genome-Wide Association Study (GWAS) and a Phenome-Wide Association Study (PheWAS) to identify the genomic variants associated with TB disease and further utilize them for drug-targeted genes. We evaluated 3.425 genomic variants associated with TB disease which overlapped with 200 TB-associated genes. To prioritize the biological TB risk genes, we devised an in-silico pipeline and leveraged an established bioinformatics method based on six functional annotations (missense mutation, *cis*-eQTL, biological process, cellular component, molecular function, and KEGG molecular pathway analysis). Interestingly, based on the six functional annotations that we applied, we discovered that 14 biological TB risk genes are strongly linked to the deregulation of the biological TB risk genes. Hence, we demonstrated that 12 drug target genes overlapped with 40 drugs for other indications and further suggested that the drugs may be repurposed for the treatment of TB. We highlighted that *CD44*, *CCR5*, *CXCR4*, and *C3* are highly promising proposed TB targets since they are connected to SELP and HLA-B, which are biological TB risk genes with high systemic scores on functional annotations. In sum, the current study shed light on the genomic variants involved in TB pathogenesis as the biological TB risk genes and provided empirical evidence that the genomics of TB may contribute to drug discovery.

Keywords: bioinformatics, drug repurposing, drug discovery, genomic variants, tuberculosis.

Introduction

Currently, tuberculosis (TB) is still a major health problem in the world. TB infection is the second leading infectious killer after corona virus disease 2019 (COVID-19) and the 13th leading cause of death [1]. Based on the Global TB Report on 2021, the estimation of TB cases was 824.000, with 393.323 notified as TB cases, 3.110 death due to TB, and 33.366 cases in pediatric. However, the treatment success rate reached 83% and the treatment coverage reached 48% [2]. The standard regimen for TB treatment still comprises isoniazid, pyrazinamide, rifampicin, and ethambutol given for two months, followed by rifampicin and isoniazid administered for four months [3]. Unfortunately, the patients still experience some side effects, such as drug resistance [4]. As such, more effective antituberculosis drugs are needed as the regimen has been less effective.

A previous review mentioned that TB patients can be categorized into three risk groups: the lowest risk group that can be treated successfully in 4 months, the moderate risk group that is treatable within 6 months, and the highest risk group that can be cured in more than 6 months due to therapy failure and relapse [5]. Moreover, the risk for adverse drug reactions, such as hepatotoxicity experienced by 2.4% of TB patients due to the combination of oral antituberculosis [3]. The hepatotoxicity due to oral antituberculosis can decrease the patients' adherence to taking TB medications, leading to treatment failure or drug resistance. Some adverse drug reactions are minor and treatable without treatment discontinuation; however, hepatotoxicity may cause treatment discontinuation [6].

In addition, there is evidence that the development of novel therapeutic agents must be focused on the treatments of Multidrug-resistant tuberculosis (MDR-TB) and Extensively drug-resistant tuberculosis (XDR-TB) [7]. Drug repurposing is an alternative way to identify new drugs for the treatment of TB by utilizing old drugs for other indications [8]. The mechanism of novel therapeutic agents may be related to the mechanisms of autophagy and apoptosis [7]. Some drugs, such as sulphonamides, sulfanilamide, sulfadiazine, carbapenem, metformin, verapamil, statin, and fluoroquinolone, are listed as targeted medications for TB, with the emphasis on the mechanisms as immunomodulators [9]. Other medications, such as bedaquline, delamanid, and pretonamid received regulatory approval as an immunomodulator tentatively. Thus, the effort to find out novel therapeutic agents for TB must be applied

after there is an accurate diagnosis to avoid drug resistance. A possible combination of the drugs must be considered carefully to determine the synergistic effects [10].

In today's era of genomic medicine, healthcare can be improved tremendously [11]. Genomic-based approach nowadays has the potential to be used for the development of new drugs using various approaches, including the bioinformatic-based approach [12]. The explosion of genomic information allows us to effectively hypothesize which drugs from one disease indication can be used for another indication; further, this information provides the opportunities for scientists to develop drugs more specifically and precisely [13]. An example of successful precision therapy used in most clinics is imatinib, which is a tyrosine kinase inhibitor originally developed for the treatment of chronic myelogenous leukaemia (CML). It was later repurposed for the treatment of gastrointestinal stromal tumors (GISTs) that possess a mutated tyrosine kinase that imatinib is also able to target. As an alternative, high-throughput screening has been used to identify novel targets on a large scale [14]. In the current study, we utilized the germline variants and prioritized the most important biological TB risk genes based on the scoring system from strict functional annotations and established a bioinformatic method. In the final step, we employed the biological TB risk genes to find drug-targeted genes for TB pharmacotherapy.

Methods

Prioritization of genomic variants associated with susceptibility to TB

Our current study utilized the Genome-Wide Association Study (GWAS) and Phenome-Wide Association Study (PheWAS) databases to identify variants associated with the susceptibility to TB disease. These two databases were accessed on March 14, 2022. GWAS and PheWAS are freely accessible databases that can help everyone find the connections between genetic variants and traits in samples from various populations. The GWAS and PheWAS studies are primarily focused on understanding the biology of diseases and provide a large number of variants associated with phenotype susceptibility [15]. Next, we prioritized the genes with strict functional annotations to identify biological TB risk genes. Further, these genes would be prioritized for drug-targeted genes based on the drug databases (**Figure 1**).

Prioritization of TB-associated Genes

We evaluated the variants that met the inclusion criteria for this study. We used the criteria of statistical significance with a *p*-value $<5x10^{-8}$ (https://www.ebi.ac.uk/gwas) for the GWAS-based approach and a *p*-value <0.05 (https://phewascatalog.org/) for the PheWAS-based approach, respectively. We ascertained that the duplicate single nucleotide polymorphisms (SNPs) were removed, and we finally focused on the unique SNPs. After identifying the variants associated with TB, we further focused on the identification of expanded variants from HaploReg version 4.1 with the criteria of r^2 value (>0.8)[16]. The aim of this step was to identify the proxy SNPs in Linkage Disequilibrium (LD) [16]. An LD value between genetic variants is commonly expressed as r^2 because this coefficient allows the detection of an association between an observed genotype and an unobserved causal variant with a linear sample size requirement. After this step, we identified 3.425 variants encoding 200 genes that would later be prioritized as TB-associated genes.

Prioritization of biological TB risk genes

We demonstrated six functional annotations as the strict criteria to prioritize the biological TB risk genes. Biological TB risk genes are crucial information that guides us to understand that genomic information plays an important role in the pathogenesis of TB based on the functional annotation criteria. The selection criteria were adopted from those of Okada Y et al., which were later prioritized for the drug repurposing for rheumatoid arthritis [16]. These annotations have also been applied for the repurposing of drugs for several other diseases, including chronic hepatitis B [17], atopic dermatitis [18], asthma [19], and colorectal cancer [20].

The following are six criteria that we used in prioritizing TB-associated genes. The first annotation that we applied was missense variants encoding genes leading to the amino acid changes in protein level [21]. Second, we assessed the *cis* expression quantitative trait loci (*cis*-eQTL) effects in the whole blood and lung tissues; gene expression signature can indicate a phenotype of the disease. Furthermore, we leveraged the fact that the *cis*-eQTL are regions with nucleotides correlated with alterations in gene expression. Therefore, the variants may cause changes in gene expression in the direction of the tissues involved (i.e., our analyses focused on the whole blood and lungs). The identified variants cause an upregulation of gene X, leading to an increased risk of TB disease. In that case, an inhibitor of its protein product

may be considered a repositioning candidate. Gene ontologies include biological process as the third criterion, cellular component as the fourth criterion, and molecular function as the fifth criterion. To construct gene ontologies, the Database for Annotation, Visualization, and Integrated Discovery (DAVID) online tool version 6.8 was used (https://david-d.ncifcrf.gov/tools.jsp) [22]. The aim of constructing these gene ontologies was to understand the relationship between diseases and biological protein networks. If the genes involved in the biological protein networks were related to TB pathogenesis, it would be important to inhibit the protein.

The criterion of the Kyoto Encyclopedia of Genes and Genomes (KEGG) was the final functional annotation that we utilized in this step. The KEGG pathway enrichment analysis was performed by using the DAVID online tool. The genes implicated in KEGG determine the types of molecular pathways enriched on the TB-associated genes. Pathway-specific signature is important to be noted as it can indicate the phenotypes of some diseases. Through the signature, we were able to understand which genes were deregulated in the phenotype of TB.

Genes overlapping with TB play a causal role in TB pathogenesis. It is important to consider the TB causal relationship and the drug-targeted genes for TB disease**.** In addition, the functional annotations that we used have been validated by Okada Y *et al*. to prioritize the most likely causal gene relationship with Rheumatoid Arthritis and to find the drug candidates for its treatment [16]. The genes that overlapped with the functional annotations were prioritized as the genes with a score of 1. We then prioritized the genes with a minimum score of 2 to identify biological TB risk genes. In our analyses, we set the threshold of a biological score ≥ 2 to find a much higher number of genes as biological TB risk genes and candidates for TB drug targets**.**

Prioritization of TB drug targets

To prioritize the TB drug targets, we leveraged the STRING database. This step aimed to expand biological TB risk genes to obtain more drug-targeted genes. Next, we mapped the drug-targeted genes onto Drug-Gene Interaction Database (DGIdb version 4.0, www.dgidb.org) [23] to find potential drugs for TB. DGIdb version 4.0 is a freely accessible database that comprehensively integrates various databases to overlap druggable genes with drugs. This database is comprehensively integrated into the drug databases, including DrugBank [24], Guide to Pharmacology [25], Gene Ontology [26], OncoKB [27], PharmGKB [28], and the Therapeutic Target Database [29].

Results

Identification of genomic variants of TB

Through the GWAS and PheWAS studies, we discovered 252 variants associated with TB susceptibility (**Supplementary Table 1**). In the next step, we utilized the HaploReg version 4 to expand the SNPs based on the proxy SNPs with the highest r^2 value (>0.8). Based on this analysis, we identified 3.425 SNPs of TB. Further, we overlapped the genomic variants of TB SNPs, and finally, we identified 200 TB-associated genes. The subsequent step was to prioritize the TB-associated genes based on the criteria of functional annotations that we demonstrated.

Identification of TB-associated genes

Based on the six functional annotations that we demonstrated, we mapped the variants onto the corresponding genes with missense/nonsense mutations as one of the non-synonymous changes in a single base substitution of different types of amino acid in the resulting protein. In this step, we identified 16 genes with missense mutations. Next, we demonstrated whether the TB-associated genes that we identified had *cis*-eQTL in the whole blood and lung tissues. Then, we utilized this annotation with the knowledge that functional rules of variants affect protein expression. Thirty-one genes with *cis*-eQTL and 19 genes with biological process, 10 genes of cellular component, 7 genes of molecular function, and 6 genes the KEGG were discovered in the current research. It is important to note that *cis*-eQTL has the highest number compared to other functional annotations. This means that the TB-associated genes that we discovered were more expressed in the blood and the lung tissues since the mycobacterium tuberculosis affected these tissues.

Identification of biological TB risk genes

Our study showed that the higher the threshold of biological score applied, the smaller the number of biological genes identified, limiting the number of drug targets we could observe (i.e., we found 1 biological TB risk gene for a threshold score >=5, 1 biological TB risk gene for a threshold score >=4, 4 biological TB risk genes for a threshold score >=3, and 8 biological TB risk genes for a threshold score >= 2). Finally, 14 biological TB risk genes were successfully identified with a threshold score >= 2 (**Table 1 and Supplementary Table 2**). The distribution score of each criterion is shown in **Figure**

2A and Figure 2B. Furthermore, we expanded 14 biological TB risk genes with 50 interactions by using the STRING database to achieve more drug-targeted genes. As a result, we found 64 drug-targeted genes of 14 expanded biological TB risk genes.

Drug candidates to be repurposed for TB

In this step, we discovered 426 gene pairs with 64 drug-targeted genes from the curated PPI networking adapted from the STRING database (**Figure 3**). To overlap the drug-targeted genes with the drug candidates, we used the DGidb drug database. Unfortunately, not all drug-targeted genes that we identified had pharmacological activities. Therefore, these might potentially miss the drug-targeted genes (undruggable). Our analysis showed that only four biological TB risk genes were linked to 12 drug-targeted genes among 64 drug-targeted genes. These 12 drug-targeted genes overlapped with 40 potential drugs for TB that were druggable (genetically-driven druggable) (**Figure 4**). We highlighted that *CD44, CCR5, CXCR4,* and *C3* are highly promising proposed TB targets since they are connected to SELP and HLA-B, which are biological TB risk genes with high systemic scores on functional annotations. The current study emphasized that the biological TB risk genes can be translated into clinical implementation through genomic variant-driven drug repurposing for TB disease.

Discussion

In the present study, we prioritized TB-associated genes for drug repurposing for TB. We hypothesized that prioritizing TB genetic variants using six functional annotations would enable us to translate and deepen our understanding of risk genes of TB pathogenesis. So far, the medications for TB patients are still limited with some side effects, such as drug resistance and low compliance of patients due to adverse events of the medications. Therefore, the rationale of the current study in response to the lack of new clinical drugs for TB was to propose drug repurposing to provide more usable therapeutic drugs for TB patients. It is most notable that the concept of drug repurposing has several advantages. The drug candidates have clear mechanisms for pharmacological action, pharmacokinetic profiles, metabolic pathways, and toxic

reactions [30]. We focused on the repurposed drugs for TB in this study based on the established bioinformatic approach.

It is important to note some findings that the following twelve promising targets overlapped with 40 drugs that could be repurposed for TB treatment: *C3*, *VWF*, *CALM1*, *CD44*, *SELP*, *NOS1*, *CCR4*, *CCR5*, *CXCR4*, *FKBP1A*, *CACNA1C*, and *RYR2*. Among the twelve promising targets, *CD44*, *CCR5*, *CXCR4*, and *C3* are highly promising TB targets since they are linked to *SELP* and *HLA-B* as biological TB risk genes with high systemic scores on functional annotations. A study conducted in Indonesia with pulmonary tuberculosis patients showed a significant association between *HLA-B*4006* and new pulmonary TB patients and between *HLA-B*1802*, *HLA-B*4001* and *HLA-DRB1**1101 with recurrent pulmonary TB [31]. This study was conducted on 257 pulmonary TB patients and 236 healthy subjects. Another study conducted in Mali also presented a significant association between *HLA-B* alleles (B*07:02, B*08:01, B*14:02, B*15:03, B*15:10, B*18:01, B*42:01, B*42:02, B*51:01 and B*81:01) and M. tuberculosis (75%) [32]. This study indicated important information regarding the genomic variants associated with TB disease.

Besides, the cytoskeleton plays a critical role in the regulation of cell migration and phagocytosis to control Mycobacterium TB infection. *CD44* is an adhesion molecule connected to the actin cytoskeleton and is implicated in inflammatory processes. *In vivo* studies showed that *CD44* plays a role in the protective immunological response to pulmonary TB, marked by decreased survival rate and increased mycobacterial outgrowth in the *CD44* mice's lungs and livers. The *CD44* protein mediates phagocytosis and recruitment of Macrophages for the eradication of pulmonary tuberculosis by mycobacterium TB [33]. As a result, *CD44* can be a promising target for the treatment of TB by using hyaluronic acid [34-36]. In this study, we identified hyaluronic acid that targeted *CD44*.

C-C Motif Chemokine Receptor 5, also known as *CCR5*, has an active role in the migration of Th1 cells and macrophages; both are crucial for the protection of immune response to Mycobacterium TB. The *CCR5* mice induced a Th1 response and controlled Mycobacterium TB infection effectively [37]. The pathogen modified *CCR5* to increase *IL-10* production during Mycobacterium TB infection, suggesting that *CCR5* might be involved in the control of the host immune response. Infection with Mycobacterium enhanced *CCR5* expression in macrophages, allowing downstream signaling to become active. *CCR5* plays a significant part in the pathogen's immune

subversion process [38]. This study found maraviroc that targeted *CCR5* so that it can be a novel drug candidate for TB therapy.

Further, our bioinformatics analysis confirmed *CXCR4* and *C3* as highly potential drug repositioning targets for TB. *CXCR4* is associated with plerixafor drug. *CXCR4* can be found mostly in alveolar macrophages. Infection of macrophages with Mycobacterium TB raised *CXCR4* surface expression *in vitro*, but illness amelioration decreased *CXCR4* expression *in vivo* [39]. In the case of TB infection, *CXCR4* can be a potential novel therapy. Next, *C3* plays an essential role in the pathogenesis and the treatment of TB [40]. Albumin and lipoprotein (a) levels increased dramatically in treated TB patients although *C3* levels decreased significantly. This result might be attributed to better inflammation, lipid metabolism, reduced immune system and complemented system activation. As a result, albumin, lipoprotein (a), and *C3* levels can be used as biomarkers to cure TB [41]. Our current research showed that genomic variants can help identify biomarker diagnostics and become drug candidates for TB at the same time.

Limitation and strengths

Our findings have not been reported so far by the previous studies that utilized genomic data and bioinformatics. However, we acknowledged that the current study still has some limitations that may not be avoidable; one of which is not all drug-targeted genes that we identified were druggable. Therefore, some of the biological TB risk genes might not overlap with the approved drugs (undruggable). Our analysis showed that only four biological TB risk genes were linked to 12 drug-targeted genes (18.75%) of 64 drug-targeted genes. These 12 drug-targeted genes overlapped with 40 potential drugs for TB that were druggable (genetically driven druggable). According to the previous study, not all drug-targeted genes are druggable, as shown in the study of Finan et al. in which only 4479 (22%) among 20,300 protein-coding genes are druggable [42]. Finally, we proposed that the functional studies (*in vitro* and *in vivo)* of the biological risk genes and the genes targeted by these drugs still require further investigation to ascertain the role of drug-targeted genes, especially in alleviating the problem of drug resistance in TB treatment.

Conclusion

In conclusion, 12 drug-targeted genes overlapped with 40 drugs for other indications that might be repurposed for TB. Among the twelve promising targets in the study, we highlighted that *CD44*, *CCR5*, *CXCR4*, and *C3* are highly promising proposed TB targets. Genomic studies are useful to identify TB-associated genes and may serve as targets for drug repurposing. This study shed light on the genomic variants that might be involved in TB pathogenesis and provided evidence that the use of genomic information can help in drug discovery.

Funding

There is no support funding for this study.

Author Contributions

L.M.I. and D.A.P conceived and designed the study. L.M.I and W.A performed the computational analysis. L.M.I wrote the manuscript. L.M.I., W.A and D.A.P revised the manuscript. L.M.I and D.A.P supervised and coordinated this study. All authors read and approved the manuscript and made significant contributions to this study.

Declaration of Competing Interest

The authors declared no conflict of interest

Abbreviations

cis-eQTL	: Cis-expression Quantitative Trait Locus
CML	: Chronic myelogenous leukaemia
COVID-19	: Corona Virus Disease 2019
DAVID	:Database for Annotation, Visualization and Integrated Discovery
DGIdb	: Drug-Gene Interaction Database
GISTs	: Gastrointestinal stromal tumours
GWAS	: Genome-Wide Association Study
KEGG	: Kyoto Encyclopedia of Genes and Genomes
LD	: Linkage Disequilibrium
MDR-TB	: Multi Drug-resistance
ORA	: Over-Representation Analysis
PheWAS	: Phenome-Wide Association Study
PID	: Primary Immuno-deficiency
PPIs	: Protein-Protein Interactions
SNP	: Single Nucleotide Polymorphism
TB	: Tuberculosis
XDR-TB	: Extensively Drug-resistance



GENCODE_id	Genes	Missense	cis-eQTL	Biological Process	Cellular Component	Molecular Function	KEGG	Total score
ENSG00000198502	HLA-DRB5	1	0	1	1	1	1	5
ENSG00000138109	CYP2C9	1	0	1	0	1	1	4
ENSG00000153707	PTPRD	0	0	1	1	1	0	3
ENSG00000171817	ZNF540	0	0	1	0	1	1	3
ENSG00000174175	SELP	1	0	1	0	0	1	3
ENSG00000234745	HLA-B	0	0	1	1	1	0	3
ENSG00000107562	CXCL12	0	0	1	0	0	1	2
ENSG00000109445	ZNF330	0	1	0	0	1	0	2
ENSG00000146938	NLGN4X	0	0	1	1	0	0	2
ENSG00000160856	FCRL3	1	1	0	0	0	0	2
ENSG00000167914	GSDMA	1	1	0	0	0	0	2
ENSG00000178607	ERN1	1	0	1	0	0	0	2
ENSG00000198626	RYR2	0	0	1	1	0	0	2
ENSG00000153162	BMP6	1	1	0	0	0	0	

Figure 1. This model illustrates how the genomic variants-based approach can be translated into clinical implantation for drug repurposing for TB.



Figure 2. Tuberculosis (TB) genomic-drug repurposing process. (**A**) Six criteria of functional annotation-derived TB biological risk genes. (**B**) Bar chart showing the number of genes and scores for each criterion.



Figure 3. Protein-protein interaction among biological TB risk genes with 426 gene pairs.



Figure 4. Identification of potential 40 drugs to be repurposed for TB which overlapped with 12 drug-targeted genes.

Table 1. Biological TB risk genes according to the six functional annotations

GENCODE_id	Genes	Missense	*cis*-eQTL	Biological Process	Cellular Component	Molecular Function	KEGG	Total score
ENSG00000198502	*HLA-DRB5*	1	0	1	1	1	1	5
ENSG00000138109	*CYP2C9*	1	0	1	0	1	1	4
ENSG00000153707	*PTPRD*	0	0	1	1	1	0	3
ENSG00000171817	*ZNF540*	0	0	1	0	1	1	3
ENSG00000174175	*SELP*	1	0	1	0	0	1	3
ENSG00000234745	*HLA-B*	0	0	1	1	1	0	3
ENSG00000107562	*CXCL12*	0	0	1	0	0	1	2
ENSG00000109445	*ZNF330*	0	1	0	0	1	0	2
ENSG00000146938	*NLGN4X*	0	0	1	1	0	0	2
ENSG00000160856	*FCRL3*	1	1	0	0	0	0	2
ENSG00000167914	*GSDMA*	1	1	0	0	0	0	2
ENSG00000178607	*ERN1*	1	0	1	0	0	0	2
ENSG00000198626	*RYR2*	0	0	1	1	0	0	2
ENSG00000153162	*BMP6*	1	1	0	0	0	0	2

References:

1. Organization, W.H. Tuberculosis. **2021**.
2. Anonymous. Dashboard of Tuberculosis in Indonesia. Health Ministry of Indonesia. .
3. Suárez, I.; Fünger, S.M.; Kröger, S.; Rademacher, J.; Fätkenheuer, G.; Rybniker, J. The Diagnosis and Treatment of Tuberculosis. *Dtsch Arztebl Int* **2019**, *116*, 729-735, doi:10.3238/arztebl.2019.0729.
4. Allué-Guardia, A.; García, J.I.; Torrelles, J.B. Evolution of Drug-Resistant Mycobacterium tuberculosis Strains and Their Adaptation to the Human Lung Environment. *Frontiers in Microbiology* **2021**, *12*.
5. Adjobimey, M.; Behr, M.A.; Menzies, D. Individualized Treatment Duration in Tuberculosis Treatment: Precision versus Simplicity. *Am J Respir Crit Care Med* **2021**, *204*, 1013-1014, doi:10.1164/rccm.202107-1744ED.
6. Prasad, R.; Singh, A.; Gupta, N. Adverse drug reactions in tuberculosis and management. *Indian J Tuberc* **2019**, *66*, 520-532, doi:10.1016/j.ijtb.2019.11.005.
7. Mourenza, Á.; Gil, J.A.; Mateos, L.M.; Letek, M. Novel Treatments against Mycobacterium tuberculosis Based on Drug Repurposing. *Antibiotics (Basel)* **2020**, *9*, doi:10.3390/antibiotics9090550.
8. Gl, B.; Rajput, R.; Gupta, M.; Dahiya, P.; Thakur, J.K.; Bhatnagar, R.; Grover, A. Structure-based drug repurposing to inhibit the DNA gyrase of Mycobacterium tuberculosis. *Biochem J* **2020**, *477*, 4167-4190, doi:10.1042/bcj20200462.
9. Fatima, S.; Bhaskar, A.; Dwivedi, V.P. Repurposing Immunomodulatory Drugs to Combat Tuberculosis. *Front Immunol* **2021**, *12*, 645485, doi:10.3389/fimmu.2021.645485.
10. Singh, V.; Chibale, K. Strategies to Combat Multi-Drug Resistance in Tuberculosis. *Acc Chem Res* **2021**, *54*, 2361-2376, doi:10.1021/acs.accounts.0c00878.
11. Green, E.D.; Guyer, M.S. Charting a course for genomic medicine from base pairs to bedside. *Nature* **2011**, *470*, 204-213, doi:10.1038/nature09764.
12. R., N. Repurposing drugs in the genomics era: bioinformatics approaches. . *MOJ Proteomics Bioinform.* **2016**, *3*, 87-88, doi:DOI: 10.15406/mojpb.2016.03.00092.
13. Lussier, Y.A.; Chen, J.L. The emergence of genome-based drug repositioning. *Sci Transl Med* **2011**, *3*, 96ps35, doi:10.1126/scitranslmed.3001512.
14. Schadt, E.E.; Friend, S.H.; Shaywitz, D.A. A network view of disease and compound screening. *Nat Rev Drug Discov* **2009**, *8*, 286-295, doi:10.1038/nrd2826.
15. Diogo, D.; Tian, C.; Franklin, C.S.; Alanne-Kinnunen, M.; March, M.; Spencer, C.C.A.; Vangjeli, C.; Weale, M.E.; Mattsson, H.; Kilpeläinen, E., et al. Phenome-wide association studies across large population cohorts support drug target validation. *Nature Communications* **2018**, *9*, 4285, doi:10.1038/s41467-018-06540-3.
16. Okada, Y.; Wu, D.; Trynka, G.; Raj, T.; Terao, C.; Ikari, K.; Kochi, Y.; Ohmura, K.; Suzuki, A.; Yoshida, S., et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery. *Nature* **2014**, *506*, 376-381, doi:10.1038/nature12873.
17. Irham, L.M.; Adikusuma, W.; Perwitasari, D.A.; Dania, H.; Maliza, R.; Faridah, I.N.; Santri, I.N.; Phiri, Y.V.A.; Cheung, R. The use of genomic variants to drive

drug repurposing for chronic hepatitis B. *Biochemistry and Biophysics Reports* **2022**, *31*, 101307, doi:https://doi.org/10.1016/j.bbrep.2022.101307.
18. Adikusuma, W.; Irham, L.M.; Chou, W.H.; Wong, H.S.; Mugiyanto, E.; Ting, J.; Perwitasari, D.A.; Chang, W.P.; Chang, W.C. Drug Repurposing for Atopic Dermatitis by Integration of Gene Networking and Genomic Information. *Front Immunol* **2021**, *12*, 724277, doi:10.3389/fimmu.2021.724277.
19. Adikusuma, W.; Chou, W.-H.; Lin, M.-R.; Ting, J.; Irham, L.M.; Perwitasari, D.A.; Chang, W.-P.; Chang, W.-C. Identification of Druggable Genes for Asthma by Integrated Genomic Network Analysis. *Biomedicines* **2022**, *10*, doi:10.3390/biomedicines10010113.
20. Irham, L.M.; Wong, H.S.-C.; Chou, W.-H.; Adikusuma, W.; Mugiyanto, E.; Huang, W.-C.; Chang, W.-C. Integration of genetic variants and gene network for drug repurposing in colorectal cancer. *Pharmacological Research* **2020**, *161*, 105203, doi:https://doi.org/10.1016/j.phrs.2020.105203.
21. Zhou, X.; Iversen, E.S., Jr.; Parmigiani, G. Classification of Missense Mutations of Disease Genes. *J Am Stat Assoc* **2005**, *100*, 51-60, doi:10.1198/016214504000001817.
22. Huang da, W.; Sherman, B.T.; Lempicki, R.A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. *Nat Protoc* **2009**, *4*, 44-57, doi:10.1038/nprot.2008.211.
23. Freshour, S.L.; Kiwala, S.; Cotto, K.C.; Coffman, A.C.; McMichael, J.F.; Song, J.J.; Griffith, M.; Griffith, O.L.; Wagner, A.H. Integration of the Drug-Gene Interaction Database (DGIdb 4.0) with open crowdsource efforts. *Nucleic Acids Res* **2021**, *49*, D1144-d1151, doi:10.1093/nar/gkaa1084.
24. Wishart, D.S.; Feunang, Y.D.; Guo, A.C.; Lo, E.J.; Marcu, A.; Grant, J.R.; Sajed, T.; Johnson, D.; Li, C.; Sayeeda, Z., et al. DrugBank 5.0: a major update to the DrugBank database for 2018. *Nucleic Acids Res* **2018**, *46*, D1074-d1082, doi:10.1093/nar/gkx1037.
25. Armstrong, J.F.; Faccenda, E.; Harding, S.D.; Pawson, A.J.; Southan, C.; Sharman, J.L.; Campo, B.; Cavanagh, D.R.; Alexander, S.P.H.; Davenport, A.P., et al. The IUPHAR/BPS Guide to PHARMACOLOGY in 2020: extending immunopharmacology content and introducing the IUPHAR/MMV Guide to Malaria Pharmacology. *Nucleic Acids Res* **2020**, *48*, D1006-d1021, doi:10.1093/nar/gkz951.
26. Ashburner, M.; Ball, C.A.; Blake, J.A.; Botstein, D.; Butler, H.; Cherry, J.M.; Davis, A.P.; Dolinski, K.; Dwight, S.S.; Eppig, J.T., et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. *Nat Genet* **2000**, *25*, 25-29, doi:10.1038/75556.
27. Chakravarty, D.; Gao, J.; Phillips, S.M.; Kundra, R.; Zhang, H.; Wang, J.; Rudolph, J.E.; Yaeger, R.; Soumerai, T.; Nissan, M.H., et al. OncoKB: A Precision Oncology Knowledge Base. *JCO Precis Oncol* **2017**, *2017*, doi:10.1200/po.17.00011.
28. Whirl-Carrillo, M.; McDonagh, E.M.; Hebert, J.M.; Gong, L.; Sangkuhl, K.; Thorn, C.F.; Altman, R.B.; Klein, T.E. Pharmacogenomics knowledge for personalized medicine. *Clin Pharmacol Ther* **2012**, *92*, 414-417, doi:10.1038/clpt.2012.96.
29. Zhou, Y.; Zhang, Y.; Lian, X.; Li, F.; Wang, C.; Zhu, F.; Qiu, Y.; Chen, Y. Therapeutic target database update 2022: facilitating drug discovery with enriched comparative data of targeted agents. *Nucleic Acids Res* **2022**, *50*, D1398-d1407, doi:10.1093/nar/gkab953.

30. Gupta, S.C.; Sung, B.; Prasad, S.; Webb, L.J.; Aggarwal, B.B. Cancer drug discovery by repurposing: teaching new tricks to old dogs. *Trends Pharmacol Sci* **2013**, *34*, 508-517, doi:10.1016/j.tips.2013.06.005.
31. Yuliwulandari, R.; Sachrowardi, Q.; Nakajima, H.; Kashiwase, K.; Hirayasu, K.; Mabuchi, A.; Sofro, A.S.M.; Tokunaga, K. Association of HLA-A, -B, and -DRB1 with pulmonary tuberculosis in western Javanese Indonesia. *Human Immunology* **2010**, *71*, 697-701, doi:https://doi.org/10.1016/j.humimm.2010.04.005.
32. Kone, A.; Diarra, B.; Cohen, K.; Diabate, S.; Kone, B.; Diakite, M.T.; Diarra, H.; Sanogo, M.; Togo, A.C.G.; Sarro, Y.D.S., et al. Differential HLA allele frequency in Mycobacterium africanum vs Mycobacterium tuberculosis in Mali. *Hla* **2019**, *93*, 24-31, doi:10.1111/tan.13448.
33. Leemans, J.C.; Florquin, S.; Heikens, M.; Pals, S.T.; van der Neut, R.; Van Der Poll, T. CD44 is a macrophage binding site for Mycobacterium tuberculosis that mediates macrophage recruitment and protective immunity against tuberculosis. *J Clin Invest* **2003**, *111*, 681-689, doi:10.1172/jci16936.
34. Riaz Khan, V.A., Sivasankar C., Deepa M. Hyaluronic Acid – TB Drug Conjugates for the Treatment of Active Tuberculosis Disease. *International journal of advanced Science and Engineering***, 2020**.
35. Thirumalaisamy, R.; Aroulmoji, V.; Iqbal, M.N.; Saride, S.; Bhuvaneswari, M.; Deepa, M.; Sivasankar, C.; Khan, R. Molecular insights of hyaluronic acid - ethambutol and hyaluronic acid - isoniazid drug conjugates act as promising novel drugs for the treatment of tuberculosis. *J Biomol Struct Dyn* **2022**, 10.1080/07391102.2022.2051748, 1-12, doi:10.1080/07391102.2022.2051748.
36. Gao, Y.; Sarfraz, M.K.; Clas, S.D.; Roa, W.; Löbenberg, R. Hyaluronic Acid-Tocopherol Succinate-Based Self-Assembling Micelles for Targeted Delivery of Rifampicin to Alveolar Macrophages. *J Biomed Nanotechnol* **2015**, *11*, 1312-1329, doi:10.1166/jbn.2015.2091.
37. Algood, H.M.; Flynn, J.L. CCR5-deficient mice control Mycobacterium tuberculosis infection despite increased pulmonary lymphocytic infiltration. *J Immunol* **2004**, *173*, 3287-3296, doi:10.4049/jimmunol.173.5.3287.
38. Das, S.; Banerjee, S.; Majumder, S.; Chowdhury, B.P.; Goswami, A.; Halder, K.; Chakraborty, U.; Pal, N.K.; Majumdar, S. Immune subversion by Mycobacterium tuberculosis through CCR5 mediated signaling: involvement of IL-10. *PLoS One* **2014**, *9*, e92477, doi:10.1371/journal.pone.0092477.
39. Hoshino, Y.; Tse, D.B.; Rochford, G.; Prabhakar, S.; Hoshino, S.; Chitkara, N.; Kuwabara, K.; Ching, E.; Raju, B.; Gold, J.A., et al. Mycobacterium tuberculosis-induced CXCR4 and chemokine expression leads to preferential X4 HIV-1 replication in human macrophages. *J Immunol* **2004**, *172*, 6251-6258, doi:10.4049/jimmunol.172.10.6251.
40. Senbagavalli, P.; Kumar, N.; Kaur, G.; Mehra, N.K.; Geetha, S.T.; Ramanathan, V.D. Major histocompatibility complex class III (C2, C4, factor B) and C3 gene variants in patients with pulmonary tuberculosis. *Hum Immunol* **2011**, *72*, 173-178, doi:10.1016/j.humimm.2010.11.002.
41. Wang, C.; Wei, L.L.; Shi, L.Y.; Pan, Z.F.; Yu, X.M.; Li, T.Y.; Liu, C.M.; Ping, Z.P.; Jiang, T.T.; Chen, Z.L., et al. Screening and identification of five serum proteins as novel potential biomarkers for cured pulmonary tuberculosis. *Sci Rep* **2015**, *5*, 15615, doi:10.1038/srep15615.
42. Finan, C.; Gaulton, A.; Kruger, F.A.; Lumbers, R.T.; Shah, T.; Engmann, J.; Galver, L.; Kelley, R.; Karlsson, A.; Santos, R. The druggable genome and

support for target identification and validation in drug development. *Science translational medicine* **2017**, *9*, eaag1166.

August 07, 2022

Dear Editors,

Please find our attached manuscript entitled "Genomic-Variants Driven Drug Repurposing for Tuberculosis by Utilizing Established Bioinformatic-Based Approach," which we are submitting for consideration for publication as an Original Research article in ***Biochemistry and Biophysics Reports*** (**BBREP-D-22-00414**). We are thankful for your insightful suggestions regarding our manuscript. Here, we are attaching the revised manuscript in accordance with the comments given by the reviewer. We have read through all the reviewers' suggestions very carefully, and made the necessary revisions based on these comments, as detailed below in a point-by-point format. The revised sections are highlighted in yellow. Finally, we would like to thank you once again for giving us the opportunity to improve our manuscript. We very much hope that these revisions are adequate. We appreciate your assistance and look forward to hearing from you.

Sincerely yours,

Prof. Dr apt Dyah Aryani Perwitasari M.Sc Ph.D

Dean of Faculty of Pharmacy,
Universitas Ahmad Dahlan, Yogyakarta, Indonesia
Jl. Prof. DR. Soepomo SH, Warungboto,
Kec. Umbulharjo, Kota Yogyakarta, Daerah Istimewa Yogyakarta

Editor and Reviewer comments:

Reviewer #1: The title and topic will be of interest to the readers of the journal, however a revision should be addressed on a few points as stated below

A: We really appreciate the comment from reviewer.

Specific comments:

Q1: Please consider using an English editing service for grammatical correction.
A1: We sincerely thank the reviewer for taking the time to review our work. We have revised the manuscript accordingly and requested professional proof-readers to improve the overall language quality. **We attached the certificate of proofread from English editor service.**

Q2: Consider firstly mentioning all abbreviations at the beginning of writing.
A2: We appreciate this comment. We have revised the manuscript according to the reviewer's suggestions by mentioning all abbreviations at the beginning of writing**.** We also provide the abbreviation of each word **[Lines 328-345]**
Line 42: tuberculosis (TB)
Line 43: corona virus disease 2019 (COVID-19)
Line 95: Genome-Wide Association Study (GWAS)
Line 96: Phenome-Wide Association Study (PheWAS)
Lines 111-112: single nucleotide polymorphisms (SNPs)
Lines 115-116: Linkage Disequilibrium (LD)
Line 133-134: *cis* expression quantitative trait loci (*cis*-eQTL)
Lines 143-144: Database for Annotation, Visualization, and Integrated Discovery (DAVID)

Q3: Some sentences in the method and results section are redundant.
A3: We sincerely thank the reviewer for taking the time to review our work. We have revised the manuscript according to the reviewer's suggestions and we ask professional proof-reader to check the redundant.

Q4: The limitation does not present only the limitations of the manuscript. I found this section poor because solutions (further research or implications) were not discussed to overcome possible limitations.
A4: Many thanks to the reviewer's comments. We sincerely thank the reviewer's suggestions. The limitation of this study has been added in the manuscript. The sentences are as following: However, we acknowledged that the current study still has some limitations that may not be avoidable; one of which is not all drug-targeted genes that we identified were druggable. Therefore, some of the biological TB risk genes might not overlap with the approved drugs (undruggable). Our analysis showed that only four biological TB risk genes were linked to 12 drug-targeted genes (18.75%) of 64 drug-targeted genes. These 12 drug-targeted genes overlapped with 40 potential

drugs for TB that were druggable (genetically driven druggable). According to the previous study, not all drug-targeted genes are druggable, as shown in the study of Finan *et al*. in which only 4479 (22%) among 20,300 protein-coding genes are druggable [42]. Finally, we proposed that the functional studies (*in vitro* and *in vivo)* of the biological risk genes and the genes targeted by these drugs still require further investigation to ascertain the role of drug-targeted genes, especially in alleviating the problem of drug resistance in TB treatment. [**lines 292-304**]

Q5: It is still unclear whether this will be applied to combat TB drug resistance or prevent the adverse events of TB drugs.

A5: Thank you for your comment. In the present study, we prioritized the genes disease and TB associated genes-driven genomic drug repurposing for TB. We hypothesized that prioritizing TB genetic variants using six functional annotations would enable us to translate and deepen our understanding of TB pathogenesis. Resistance and the adverse event of TB drugs are still problem in the treatment of TB patients. Despite extensive investigation, there are currently no disease-modifying drugs available that can halt the progression of TB. Unfortunately, the discovery of new drugs is a high cost and expensive as well as time-consuming process. Therefore, the rationales of the current study in response to the lack of new clinical drugs, we repurposed drug for TB]. In estimation It takes around ∼15 years with more than $1 billion to develop and bring a new drug to market. Under such circumstances, drug repositioning, which is the identification of new indications for existing drugs, is thought to be a promising strategy for intractable diseases including TB.

Our finding revealed that 12 drug target genes overlapped with 40 drugs for other indications that might be promised to be repurposed for TB. Among the twelve promising targets, we highlighted that *CD44*, *CCR5*, *CXCR4*, and *C3* are highly proposed potential TB targets. Genomic studies are useful tools to identify associated genes and may serve as targets for drug repurposing. This study shed light on the genomic variations that might play a role in TB pathogenesis and offered evidence that the use of genomic information can help in drug discovery.

However, we acknowledged that the current study still has some limitations that may not be avoidable; one of which is not all drug-targeted genes that we identified were druggable. Therefore, some of the biological TB risk genes might not overlap with the approved drugs (undruggable). Our analysis showed that only four biological TB risk genes were linked to 12 drug-targeted genes (18.75%) of 64 drug-targeted genes. These 12 drug-targeted genes overlapped with 40 potential drugs for TB that were druggable (genetically driven druggable). According to the previous study, not all drug-targeted genes are druggable, as shown in the study of Finan *et al*. in which only 4479 (22%) among 20,300 protein-coding genes are druggable [42]. Finally, we proposed that the functional studies (*in vitro* and *in vivo)* of the biological risk genes and the genes targeted by these drugs still require further investigation to ascertain the role of

drug-targeted genes, especially in alleviating the problem of drug resistance in TB treatment. **[lines 291-304].**

Q6: Additional comments: This manuscript is largely descriptive but provides interesting insights on drug repurposing and strategies to approach this topic. However, English must be improved before acceptance. Resolution of most images is poor and need to be fixed. Figure legends are poorly described.

A6: We sincerely thank the reviewer for taking the time to review our work. We have revised the manuscript accordingly and requested professional proof-readers to improve the overall language quality. We further change the figure into higher resolution based on the standard of journals. [**Figure 1 and Figure 4**]

SydNA Translations
Unlock the world

CERTIFICATE OF PROOFREADING

NO. 0089/SYDNA-TRANS/VIII/2022

This is to certify that the manuscript entitled:

"Genomic Variant-Driven Drug Repurposing for Tuberculosis by Utilizing the Established Bioinformatic-Based Approach"

written by:

Lalu Muhammad Irham, Wirawan Adikusuma, Dyah Aryani Perwitasari

has been proofread by a professional proofreader at SydNA Translations for the accuracy of the language, punctuation, spelling, and grammar use.
The manuscript has been returned to the customer on

August 5, 2022

SYDNA TRANSLATIONS Unlock the world

SABRINA
Chief Executive Officer
SydNa Translations

Highlights

- The feasibility of utilizing genomic variants to facilitate drug repurposing for Tuberculosis.
- Genomic information can be effectively used for drug discovery and treatment through genomic-based therapies.
- Findings from our research support the possibility of drug repurposing for Tuberculosis based on genomic variations.

Declaration of interests

☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

☐The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:

Research article

Genomic Variants-Driven Drug Repurposing for Tuberculosis by Utilizing the Established Bioinformatic-Based Approach

Lalu Muhammad Irham[1]., Wirawan Adikusuma[2]., Dyah Aryani Perwitasari[1]*

[1]Faculty of Pharmacy, Universitas Ahmad Dahlan, Yogyakarta, Indonesia

[2]Departement of Pharmacy, University of Muhammadiyah Mataram, Mataram, Indonesia.

***Correspondence:** Dyah Aryani Perwitasari; email:*dyah.perwitasari@pharm.uad.ac.id*

Abstract

A major challenge in translating genomic variants of Tuberculosis (TB) into clinical implementation is to integrate the disease-associated variants and facilitate drug discovery through the concept of genomic-driven drug repurposing. Here, we utilized two established genomic databases, namely a Genome-Wide Association Study (GWAS) and a Phenome-Wide Association Study (PheWAS) to identify the genomic variants associated with TB disease and further utilize them for drug-targeted genes. We evaluated 3.425 genomic variants associated with TB disease which overlapped with 200 TB-associated genes. To prioritize the biological TB risk genes, we devised an in-silico pipeline and leveraged an established bioinformatics method based on six functional annotations (missense mutation, *cis*-eQTL, biological process, cellular component, molecular function, and KEGG molecular pathway analysis). Interestingly, based on the six functional annotations that we applied, we discovered that 14 biological TB risk genes are strongly linked to the deregulation of the biological TB risk genes. Hence, we demonstrated that 12 drug target genes overlapped with 40 drugs for other indications and further suggested that the drugs may be repurposed for the treatment of TB. We highlighted that *CD44*, *CCR5*, *CXCR4*, and *C3* are highly promising proposed TB targets since they are connected to SELP and HLA-B, which are biological TB risk genes with high systemic scores on functional annotations. In sum, the current study shed light on the genomic variants involved in TB pathogenesis as the biological TB risk genes and provided empirical evidence that the genomics of TB may contribute to drug discovery.

Keywords: bioinformatics, drug repurposing, drug discovery, genomic variants, tuberculosis.

Introduction

Currently, tuberculosis (TB) is still a major health problem in the world. TB infection is the second leading infectious killer after corona virus disease 2019 (COVID-19) and the 13th leading cause of death [1]. Based on the Global TB Report on 2021, the estimation of TB cases was 824.000, with 393.323 notified as TB cases, 3.110 death due to TB, and 33.366 cases in pediatric. However, the treatment success rate reached 83% and the treatment coverage reached 48% [2]. The standard regimen for TB treatment still comprises isoniazid, pyrazinamide, rifampicin, and ethambutol given for two months, followed by rifampicin and isoniazid administered for four months [3]. Unfortunately, the patients still experience some side effects, such as drug resistance [4]. As such, more effective antituberculosis drugs are needed as the regimen has been less effective.

A previous review mentioned that TB patients can be categorized into three risk groups: the lowest risk group that can be treated successfully in 4 months, the moderate risk group that is treatable within 6 months, and the highest risk group that can be cured in more than 6 months due to therapy failure and relapse [5]. Moreover, the risk for adverse drug reactions, such as hepatotoxicity experienced by 2.4% of TB patients due to the combination of oral antituberculosis [3]. The hepatotoxicity due to oral antituberculosis can decrease the patients' adherence to taking TB medications, leading to treatment failure or drug resistance. Some adverse drug reactions are minor and treatable without treatment discontinuation; however, hepatotoxicity may cause treatment discontinuation [6].

In addition, there is evidence that the development of novel therapeutic agents must be focused on the treatments of Multidrug-resistant tuberculosis (MDR-TB) and Extensively drug-resistant tuberculosis (XDR-TB) [7]. Drug repurposing is an alternative way to identify new drugs for the treatment of TB by utilizing old drugs for other indications [8]. The mechanism of novel therapeutic agents may be related to the mechanisms of autophagy and apoptosis [7]. Some drugs, such as sulphonamides, sulfanilamide, sulfadiazine, carbapenem, metformin, verapamil, statin, and fluoroquinolone, are listed as targeted medications for TB, with the emphasis on the mechanisms as immunomodulators [9]. Other medications, such as bedaquline, delamanid, and pretonamid received regulatory approval as an immunomodulator tentatively. Thus, the effort to find out novel therapeutic agents for TB must be applied

after there is an accurate diagnosis to avoid drug resistance. A possible combination of the drugs must be considered carefully to determine the synergistic effects [10].

In today's era of genomic medicine, healthcare can be improved tremendously [11]. Genomic-based approach nowadays has the potential to be used for the development of new drugs using various approaches, including the bioinformatic-based approach [12]. The explosion of genomic information allows us to effectively hypothesize which drugs from one disease indication can be used for another indication; further, this information provides the opportunities for scientists to develop drugs more specifically and precisely [13]. An example of successful precision therapy used in most clinics is imatinib, which is a tyrosine kinase inhibitor originally developed for the treatment of chronic myelogenous leukaemia (CML). It was later repurposed for the treatment of gastrointestinal stromal tumors (GISTs) that possess a mutated tyrosine kinase that imatinib is also able to target. As an alternative, high-throughput screening has been used to identify novel targets on a large scale [14]. In the current study, we utilized the germline variants and prioritized the most important biological TB risk genes based on the scoring system from strict functional annotations and established a bioinformatic method. In the final step, we employed the biological TB risk genes to find drug-targeted genes for TB pharmacotherapy.

Methods

Prioritization of genomic variants associated with susceptibility to TB

Our current study utilized the Genome-Wide Association Study (GWAS) and Phenome-Wide Association Study (PheWAS) databases to identify variants associated with the susceptibility to TB disease. These two databases were accessed on March 14, 2022. GWAS and PheWAS are freely accessible databases that can help everyone find the connections between genetic variants and traits in samples from various populations. The GWAS and PheWAS studies are primarily focused on understanding the biology of diseases and provide a large number of variants associated with phenotype susceptibility [15]. Next, we prioritized the genes with strict functional annotations to identify biological TB risk genes. Further, these genes would be prioritized for drug-targeted genes based on the drug databases (**Figure 1**).

Prioritization of TB-associated Genes

We evaluated the variants that met the inclusion criteria for this study. We used the criteria of statistical significance with a *p*-value $<5x10^{-8}$ (https://www.ebi.ac.uk/gwas) for the GWAS-based approach and a *p*-value <0.05 (https://phewascatalog.org/) for the PheWAS-based approach, respectively. We ascertained that the duplicate single nucleotide polymorphisms (SNPs) were removed, and we finally focused on the unique SNPs. After identifying the variants associated with TB, we further focused on the identification of expanded variants from HaploReg version 4.1 with the criteria of r^2 value (>0.8)[16]. The aim of this step was to identify the proxy SNPs in Linkage Disequilibrium (LD) [16]. An LD value between genetic variants is commonly expressed as r^2 because this coefficient allows the detection of an association between an observed genotype and an unobserved causal variant with a linear sample size requirement. After this step, we identified 3.425 variants encoding 200 genes that would later be prioritized as TB-associated genes.

Prioritization of biological TB risk genes

We demonstrated six functional annotations as the strict criteria to prioritize the biological TB risk genes. Biological TB risk genes are crucial information that guides us to understand that genomic information plays an important role in the pathogenesis of TB based on the functional annotation criteria. The selection criteria were adopted from those of Okada Y et al., which were later prioritized for the drug repurposing for rheumatoid arthritis [16]. These annotations have also been applied for the repurposing of drugs for several other diseases, including chronic hepatitis B [17], atopic dermatitis [18], asthma [19], and colorectal cancer [20].

The following are six criteria that we used in prioritizing TB-associated genes. The first annotation that we applied was missense variants encoding genes leading to the amino acid changes in protein level [21]. Second, we assessed the *cis* expression quantitative trait loci (*cis*-eQTL) effects in the whole blood and lung tissues; gene expression signature can indicate a phenotype of the disease. Furthermore, we leveraged the fact that the *cis*-eQTL are regions with nucleotides correlated with alterations in gene expression. Therefore, the variants may cause changes in gene expression in the direction of the tissues involved (i.e., our analyses focused on the whole blood and lungs). The identified variants cause an upregulation of gene X, leading to an increased risk of TB disease. In that case, an inhibitor of its protein product

may be considered a repositioning candidate. Gene ontologies include biological process as the third criterion, cellular component as the fourth criterion, and molecular function as the fifth criterion. To construct gene ontologies, the Database for Annotation, Visualization, and Integrated Discovery (DAVID) online tool version 6.8 was used (https://david-d.ncifcrf.gov/tools.jsp) [22]. The aim of constructing these gene ontologies was to understand the relationship between diseases and biological protein networks. If the genes involved in the biological protein networks were related to TB pathogenesis, it would be important to inhibit the protein.

The criterion of the Kyoto Encyclopedia of Genes and Genomes (KEGG) was the final functional annotation that we utilized in this step. The KEGG pathway enrichment analysis was performed by using the DAVID online tool. The genes implicated in KEGG determine the types of molecular pathways enriched on the TB-associated genes. Pathway-specific signature is important to be noted as it can indicate the phenotypes of some diseases. Through the signature, we were able to understand which genes were deregulated in the phenotype of TB.

Genes overlapping with TB play a causal role in TB pathogenesis. It is important to consider the TB causal relationship and the drug-targeted genes for TB disease**.** In addition, the functional annotations that we used have been validated by Okada Y *et al*. to prioritize the most likely causal gene relationship with Rheumatoid Arthritis and to find the drug candidates for its treatment [16]. The genes that overlapped with the functional annotations were prioritized as the genes with a score of 1. We then prioritized the genes with a minimum score of 2 to identify biological TB risk genes. In our analyses, we set the threshold of a biological score ≥ 2 to find a much higher number of genes as biological TB risk genes and candidates for TB drug targets**.**

Prioritization of TB drug targets

To prioritize the TB drug targets, we leveraged the STRING database. This step aimed to expand biological TB risk genes to obtain more drug-targeted genes. Next, we mapped the drug-targeted genes onto Drug-Gene Interaction Database (DGIdb version 4.0, www.dgidb.org) [23] to find potential drugs for TB. DGIdb version 4.0 is a freely accessible database that comprehensively integrates various databases to overlap druggable genes with drugs. This database is comprehensively integrated into the drug databases, including DrugBank [24], Guide to Pharmacology [25], Gene Ontology [26], OncoKB [27], PharmGKB [28], and the Therapeutic Target Database [29].

Results

Identification of genomic variants of TB

Through the GWAS and PheWAS studies, we discovered 252 variants associated with TB susceptibility (**Supplementary Table 1**). In the next step, we utilized the HaploReg version 4 to expand the SNPs based on the proxy SNPs with the highest r^2 value (>0.8). Based on this analysis, we identified 3.425 SNPs of TB. Further, we overlapped the genomic variants of TB SNPs, and finally, we identified 200 TB-associated genes. The subsequent step was to prioritize the TB-associated genes based on the criteria of functional annotations that we demonstrated.

Identification of TB-associated genes

Based on the six functional annotations that we demonstrated, we mapped the variants onto the corresponding genes with missense/nonsense mutations as one of the non-synonymous changes in a single base substitution of different types of amino acid in the resulting protein. In this step, we identified 16 genes with missense mutations. Next, we demonstrated whether the TB-associated genes that we identified had *cis*-eQTL in the whole blood and lung tissues. Then, we utilized this annotation with the knowledge that functional rules of variants affect protein expression. Thirty-one genes with *cis*-eQTL and 19 genes with biological process, 10 genes of cellular component, 7 genes of molecular function, and 6 genes the KEGG were discovered in the current research. It is important to note that *cis*-eQTL has the highest number compared to other functional annotations. This means that the TB-associated genes that we discovered were more expressed in the blood and the lung tissues since the mycobacterium tuberculosis affected these tissues.

Identification of biological TB risk genes

Our study showed that the higher the threshold of biological score applied, the smaller the number of biological genes identified, limiting the number of drug targets we could observe (i.e., we found 1 biological TB risk gene for a threshold score >=5, 1 biological TB risk gene for a threshold score >=4, 4 biological TB risk genes for a threshold score >=3, and 8 biological TB risk genes for a threshold score >= 2). Finally, 14 biological TB risk genes were successfully identified with a threshold score >= 2 (**Table 1 and Supplementary Table 2**). The distribution score of each criterion is shown in **Figure**

2A and Figure 2B. Furthermore, we expanded 14 biological TB risk genes with 50 interactions by using the STRING database to achieve more drug-targeted genes. As a result, we found 64 drug-targeted genes of 14 expanded biological TB risk genes.

Drug candidates to be repurposed for TB

In this step, we discovered 426 gene pairs with 64 drug-targeted genes from the curated PPI networking adapted from the STRING database (**Figure 3**). To overlap the drug-targeted genes with the drug candidates, we used the DGidb drug database. Unfortunately, not all drug-targeted genes that we identified had pharmacological activities. Therefore, these might potentially miss the drug-targeted genes (undruggable). Our analysis showed that only four biological TB risk genes were linked to 12 drug-targeted genes among 64 drug-targeted genes. These 12 drug-targeted genes overlapped with 40 potential drugs for TB that were druggable (genetically-driven druggable) (**Figure 4**). We highlighted that *CD44, CCR5, CXCR4,* and *C3* are highly promising proposed TB targets since they are connected to SELP and HLA-B, which are biological TB risk genes with high systemic scores on functional annotations. The current study emphasized that the biological TB risk genes can be translated into clinical implementation through genomic variant-driven drug repurposing for TB disease.

Discussion

In the present study, we prioritized TB-associated genes for drug repurposing for TB. We hypothesized that prioritizing TB genetic variants using six functional annotations would enable us to translate and deepen our understanding of risk genes of TB pathogenesis. So far, the medications for TB patients are still limited with some side effects, such as drug resistance and low compliance of patients due to adverse events of the medications. Therefore, the rationale of the current study in response to the lack of new clinical drugs for TB was to propose drug repurposing to provide more usable therapeutic drugs for TB patients. It is most notable that the concept of drug repurposing has several advantages. The drug candidates have clear mechanisms for pharmacological action, pharmacokinetic profiles, metabolic pathways, and toxic

reactions [30]. We focused on the repurposed drugs for TB in this study based on the established bioinformatic approach.

It is important to note some findings that the following twelve promising targets overlapped with 40 drugs that could be repurposed for TB treatment: *C3*, *VWF*, *CALM1*, *CD44*, *SELP*, *NOS1*, *CCR4*, *CCR5*, *CXCR4*, *FKBP1A*, *CACNA1C*, and *RYR2*. Among the twelve promising targets, *CD44*, *CCR5*, *CXCR4*, and *C3* are highly promising TB targets since they are linked to *SELP* and *HLA-B* as biological TB risk genes with high systemic scores on functional annotations. A study conducted in Indonesia with pulmonary tuberculosis patients showed a significant association between *HLA-B*4006* and new pulmonary TB patients and between *HLA-B*1802*, *HLA-B*4001* and *HLA-DRB1**1101 with recurrent pulmonary TB [31]. This study was conducted on 257 pulmonary TB patients and 236 healthy subjects. Another study conducted in Mali also presented a significant association between *HLA-B* alleles (B*07:02, B*08:01, B*14:02, B*15:03, B*15:10, B*18:01, B*42:01, B*42:02, B*51:01 and B*81:01) and M. tuberculosis (75%) [32]. This study indicated important information regarding the genomic variants associated with TB disease.

Besides, the cytoskeleton plays a critical role in the regulation of cell migration and phagocytosis to control Mycobacterium TB infection. *CD44* is an adhesion molecule connected to the actin cytoskeleton and is implicated in inflammatory processes. *In vivo* studies showed that *CD44* plays a role in the protective immunological response to pulmonary TB, marked by decreased survival rate and increased mycobacterial outgrowth in the *CD44* mice's lungs and livers. The *CD44* protein mediates phagocytosis and recruitment of Macrophages for the eradication of pulmonary tuberculosis by mycobacterium TB [33]. As a result, *CD44* can be a promising target for the treatment of TB by using hyaluronic acid [34-36]. In this study, we identified hyaluronic acid that targeted *CD44*.

C-C Motif Chemokine Receptor 5, also known as *CCR5*, has an active role in the migration of Th1 cells and macrophages; both are crucial for the protection of immune response to Mycobacterium TB. The *CCR5* mice induced a Th1 response and controlled Mycobacterium TB infection effectively [37]. The pathogen modified *CCR5* to increase *IL-10* production during Mycobacterium TB infection, suggesting that *CCR5* might be involved in the control of the host immune response. Infection with Mycobacterium enhanced *CCR5* expression in macrophages, allowing downstream signaling to become active. *CCR5* plays a significant part in the pathogen's immune

subversion process [38]. This study found maraviroc that targeted *CCR5* so that it can be a novel drug candidate for TB therapy.

Further, our bioinformatics analysis confirmed *CXCR4* and *C3* as highly potential drug repositioning targets for TB. *CXCR4* is associated with plerixafor drug. *CXCR4* can be found mostly in alveolar macrophages. Infection of macrophages with Mycobacterium TB raised *CXCR4* surface expression *in vitro*, but illness amelioration decreased *CXCR4* expression *in vivo* [39]. In the case of TB infection, *CXCR4* can be a potential novel therapy. Next, *C3* plays an essential role in the pathogenesis and the treatment of TB [40]. Albumin and lipoprotein (a) levels increased dramatically in treated TB patients although *C3* levels decreased significantly. This result might be attributed to better inflammation, lipid metabolism, reduced immune system and complemented system activation. As a result, albumin, lipoprotein (a), and *C3* levels can be used as biomarkers to cure TB [41]. Our current research showed that genomic variants can help identify biomarker diagnostics and become drug candidates for TB at the same time.

Limitation and strengths

Our findings have not been reported so far by the previous studies that utilized genomic data and bioinformatics. However, we acknowledged that the current study still has some limitations that may not be avoidable; one of which is not all drug-targeted genes that we identified were druggable. Therefore, some of the biological TB risk genes might not overlap with the approved drugs (undruggable). Our analysis showed that only four biological TB risk genes were linked to 12 drug-targeted genes (18.75%) of 64 drug-targeted genes. These 12 drug-targeted genes overlapped with 40 potential drugs for TB that were druggable (genetically driven druggable). According to the previous study, not all drug-targeted genes are druggable, as shown in the study of Finan et al. in which only 4479 (22%) among 20,300 protein-coding genes are druggable [42]. Finally, we proposed that the functional studies (*in vitro* and *in vivo)* of the biological risk genes and the genes targeted by these drugs still require further investigation to ascertain the role of drug-targeted genes, especially in alleviating the problem of drug resistance in TB treatment.

Conclusion

In conclusion, 12 drug-targeted genes overlapped with 40 drugs for other indications that might be repurposed for TB. Among the twelve promising targets in the study, we highlighted that *CD44*, *CCR5*, *CXCR4*, and *C3* are highly promising proposed TB targets. Genomic studies are useful to identify TB-associated genes and may serve as targets for drug repurposing. This study shed light on the genomic variants that might be involved in TB pathogenesis and provided evidence that the use of genomic information can help in drug discovery.

Funding

There is no support funding for this study.

Author Contributions

L.M.I. and D.A.P conceived and designed the study. L.M.I and W.A performed the computational analysis. L.M.I wrote the manuscript. L.M.I., W.A and D.A.P revised the manuscript. L.M.I and D.A.P supervised and coordinated this study. All authors read and approved the manuscript and made significant contributions to this study.

Declaration of Competing Interest

The authors declared no conflict of interest

Abbreviations

cis-eQTL	: Cis-expression Quantitative Trait Locus
CML	: Chronic myelogenous leukaemia
COVID-19	: Corona Virus Disease 2019
DAVID	:Database for Annotation, Visualization and Integrated Discovery
DGIdb	: Drug-Gene Interaction Database
GISTs	: Gastrointestinal stromal tumours
GWAS	: Genome-Wide Association Study
KEGG	: Kyoto Encyclopedia of Genes and Genomes
LD	: Linkage Disequilibrium
MDR-TB	: Multi Drug-resistance
ORA	: Over-Representation Analysis
PheWAS	: Phenome-Wide Association Study
PID	: Primary Immuno-deficiency
PPIs	: Protein-Protein Interactions
SNP	: Single Nucleotide Polymorphism
TB	: Tuberculosis
XDR-TB	: Extensively Drug-resistance



GENCODE_id	Genes	Missense	cis-eQTL	Biological Process	Cellular Component	Molecular Function	KEGG	Total score
ENSG00000198502	HLA-DRB5	1	0	1	1	1	1	5
ENSG00000138109	CYP2C9	1	0	1	0	1	1	4
ENSG00000153707	PTPRD	0	0	1	1	1	0	3
ENSG00000171817	ZNF540	0	0	1	0	1	1	3
ENSG00000174175	SELP	1	0	1	0	0	1	3
ENSG00000234745	HLA-B	0	0	1	1	1	0	3
ENSG00000107562	CXCL12	0	0	1	0	0	1	2
ENSG00000109445	ZNF330	0	1	0	0	1	0	2
ENSG00000146938	NLGN4X	0	0	1	1	0	0	2
ENSG00000160856	FCRL3	1	1	0	0	0	0	2
ENSG00000167914	GSDMA	1	1	0	0	0	0	2
ENSG00000178607	ERN1	1	0	1	0	0	0	2
ENSG00000198626	RYR2	0	0	1	1	0	0	2
ENSG00000153162	BMP6	1	1	0	0	0	0	

Figure 1. This model illustrates how the genomic variants-based approach can be translated into clinical implantation for drug repurposing for TB.



Figure 2. Tuberculosis (TB) genomic-drug repurposing process. (**A**) Six criteria of functional annotation-derived TB biological risk genes. (**B**) Bar chart showing the number of genes and scores for each criterion.



Figure 3. Protein-protein interaction among biological TB risk genes with 426 gene pairs.



Figure 4. Identification of potential 40 drugs to be repurposed for TB which overlapped with 12 drug-targeted genes.

Table 1. Biological TB risk genes according to the six functional annotations

GENCODE_id	Genes	Missense	*cis*-eQTL	Biological Process	Cellular Component	Molecular Function	KEGG	Total score
ENSG00000198502	*HLA-DRB5*	1	0	1	1	1	1	5
ENSG00000138109	*CYP2C9*	1	0	1	0	1	1	4
ENSG00000153707	*PTPRD*	0	0	1	1	1	0	3
ENSG00000171817	*ZNF540*	0	0	1	0	1	1	3
ENSG00000174175	*SELP*	1	0	1	0	0	1	3
ENSG00000234745	*HLA-B*	0	0	1	1	1	0	3
ENSG00000107562	*CXCL12*	0	0	1	0	0	1	2
ENSG00000109445	*ZNF330*	0	1	0	0	1	0	2
ENSG00000146938	*NLGN4X*	0	0	1	1	0	0	2
ENSG00000160856	*FCRL3*	1	1	0	0	0	0	2
ENSG00000167914	*GSDMA*	1	1	0	0	0	0	2
ENSG00000178607	*ERN1*	1	0	1	0	0	0	2
ENSG00000198626	*RYR2*	0	0	1	1	0	0	2
ENSG00000153162	*BMP6*	1	1	0	0	0	0	2

References:

1. Organization, W.H. Tuberculosis. **2021**.
2. Anonymous. Dashboard of Tuberculosis in Indonesia. Health Ministry of Indonesia. .
3. Suárez, I.; Fünger, S.M.; Kröger, S.; Rademacher, J.; Fätkenheuer, G.; Rybniker, J. The Diagnosis and Treatment of Tuberculosis. *Dtsch Arztebl Int* **2019**, *116*, 729-735, doi:10.3238/arztebl.2019.0729.
4. Allué-Guardia, A.; García, J.I.; Torrelles, J.B. Evolution of Drug-Resistant Mycobacterium tuberculosis Strains and Their Adaptation to the Human Lung Environment. *Frontiers in Microbiology* **2021**, *12*.
5. Adjobimey, M.; Behr, M.A.; Menzies, D. Individualized Treatment Duration in Tuberculosis Treatment: Precision versus Simplicity. *Am J Respir Crit Care Med* **2021**, *204*, 1013-1014, doi:10.1164/rccm.202107-1744ED.
6. Prasad, R.; Singh, A.; Gupta, N. Adverse drug reactions in tuberculosis and management. *Indian J Tuberc* **2019**, *66*, 520-532, doi:10.1016/j.ijtb.2019.11.005.
7. Mourenza, Á.; Gil, J.A.; Mateos, L.M.; Letek, M. Novel Treatments against Mycobacterium tuberculosis Based on Drug Repurposing. *Antibiotics (Basel)* **2020**, *9*, doi:10.3390/antibiotics9090550.
8. Gl, B.; Rajput, R.; Gupta, M.; Dahiya, P.; Thakur, J.K.; Bhatnagar, R.; Grover, A. Structure-based drug repurposing to inhibit the DNA gyrase of Mycobacterium tuberculosis. *Biochem J* **2020**, *477*, 4167-4190, doi:10.1042/bcj20200462.
9. Fatima, S.; Bhaskar, A.; Dwivedi, V.P. Repurposing Immunomodulatory Drugs to Combat Tuberculosis. *Front Immunol* **2021**, *12*, 645485, doi:10.3389/fimmu.2021.645485.
10. Singh, V.; Chibale, K. Strategies to Combat Multi-Drug Resistance in Tuberculosis. *Acc Chem Res* **2021**, *54*, 2361-2376, doi:10.1021/acs.accounts.0c00878.
11. Green, E.D.; Guyer, M.S. Charting a course for genomic medicine from base pairs to bedside. *Nature* **2011**, *470*, 204-213, doi:10.1038/nature09764.
12. R., N. Repurposing drugs in the genomics era: bioinformatics approaches. . *MOJ Proteomics Bioinform.* **2016**, *3*, 87-88, doi:DOI: 10.15406/mojpb.2016.03.00092.
13. Lussier, Y.A.; Chen, J.L. The emergence of genome-based drug repositioning. *Sci Transl Med* **2011**, *3*, 96ps35, doi:10.1126/scitranslmed.3001512.
14. Schadt, E.E.; Friend, S.H.; Shaywitz, D.A. A network view of disease and compound screening. *Nat Rev Drug Discov* **2009**, *8*, 286-295, doi:10.1038/nrd2826.
15. Diogo, D.; Tian, C.; Franklin, C.S.; Alanne-Kinnunen, M.; March, M.; Spencer, C.C.A.; Vangjeli, C.; Weale, M.E.; Mattsson, H.; Kilpeläinen, E., et al. Phenome-wide association studies across large population cohorts support drug target validation. *Nature Communications* **2018**, *9*, 4285, doi:10.1038/s41467-018-06540-3.
16. Okada, Y.; Wu, D.; Trynka, G.; Raj, T.; Terao, C.; Ikari, K.; Kochi, Y.; Ohmura, K.; Suzuki, A.; Yoshida, S., et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery. *Nature* **2014**, *506*, 376-381, doi:10.1038/nature12873.
17. Irham, L.M.; Adikusuma, W.; Perwitasari, D.A.; Dania, H.; Maliza, R.; Faridah, I.N.; Santri, I.N.; Phiri, Y.V.A.; Cheung, R. The use of genomic variants to drive

drug repurposing for chronic hepatitis B. *Biochemistry and Biophysics Reports* **2022**, *31*, 101307, doi:https://doi.org/10.1016/j.bbrep.2022.101307.
18. Adikusuma, W.; Irham, L.M.; Chou, W.H.; Wong, H.S.; Mugiyanto, E.; Ting, J.; Perwitasari, D.A.; Chang, W.P.; Chang, W.C. Drug Repurposing for Atopic Dermatitis by Integration of Gene Networking and Genomic Information. *Front Immunol* **2021**, *12*, 724277, doi:10.3389/fimmu.2021.724277.
19. Adikusuma, W.; Chou, W.-H.; Lin, M.-R.; Ting, J.; Irham, L.M.; Perwitasari, D.A.; Chang, W.-P.; Chang, W.-C. Identification of Druggable Genes for Asthma by Integrated Genomic Network Analysis. *Biomedicines* **2022**, *10*, doi:10.3390/biomedicines10010113.
20. Irham, L.M.; Wong, H.S.-C.; Chou, W.-H.; Adikusuma, W.; Mugiyanto, E.; Huang, W.-C.; Chang, W.-C. Integration of genetic variants and gene network for drug repurposing in colorectal cancer. *Pharmacological Research* **2020**, *161*, 105203, doi:https://doi.org/10.1016/j.phrs.2020.105203.
21. Zhou, X.; Iversen, E.S., Jr.; Parmigiani, G. Classification of Missense Mutations of Disease Genes. *J Am Stat Assoc* **2005**, *100*, 51-60, doi:10.1198/016214504000001817.
22. Huang da, W.; Sherman, B.T.; Lempicki, R.A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. *Nat Protoc* **2009**, *4*, 44-57, doi:10.1038/nprot.2008.211.
23. Freshour, S.L.; Kiwala, S.; Cotto, K.C.; Coffman, A.C.; McMichael, J.F.; Song, J.J.; Griffith, M.; Griffith, O.L.; Wagner, A.H. Integration of the Drug-Gene Interaction Database (DGIdb 4.0) with open crowdsource efforts. *Nucleic Acids Res* **2021**, *49*, D1144-d1151, doi:10.1093/nar/gkaa1084.
24. Wishart, D.S.; Feunang, Y.D.; Guo, A.C.; Lo, E.J.; Marcu, A.; Grant, J.R.; Sajed, T.; Johnson, D.; Li, C.; Sayeeda, Z., et al. DrugBank 5.0: a major update to the DrugBank database for 2018. *Nucleic Acids Res* **2018**, *46*, D1074-d1082, doi:10.1093/nar/gkx1037.
25. Armstrong, J.F.; Faccenda, E.; Harding, S.D.; Pawson, A.J.; Southan, C.; Sharman, J.L.; Campo, B.; Cavanagh, D.R.; Alexander, S.P.H.; Davenport, A.P., et al. The IUPHAR/BPS Guide to PHARMACOLOGY in 2020: extending immunopharmacology content and introducing the IUPHAR/MMV Guide to Malaria Pharmacology. *Nucleic Acids Res* **2020**, *48*, D1006-d1021, doi:10.1093/nar/gkz951.
26. Ashburner, M.; Ball, C.A.; Blake, J.A.; Botstein, D.; Butler, H.; Cherry, J.M.; Davis, A.P.; Dolinski, K.; Dwight, S.S.; Eppig, J.T., et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. *Nat Genet* **2000**, *25*, 25-29, doi:10.1038/75556.
27. Chakravarty, D.; Gao, J.; Phillips, S.M.; Kundra, R.; Zhang, H.; Wang, J.; Rudolph, J.E.; Yaeger, R.; Soumerai, T.; Nissan, M.H., et al. OncoKB: A Precision Oncology Knowledge Base. *JCO Precis Oncol* **2017**, *2017*, doi:10.1200/po.17.00011.
28. Whirl-Carrillo, M.; McDonagh, E.M.; Hebert, J.M.; Gong, L.; Sangkuhl, K.; Thorn, C.F.; Altman, R.B.; Klein, T.E. Pharmacogenomics knowledge for personalized medicine. *Clin Pharmacol Ther* **2012**, *92*, 414-417, doi:10.1038/clpt.2012.96.
29. Zhou, Y.; Zhang, Y.; Lian, X.; Li, F.; Wang, C.; Zhu, F.; Qiu, Y.; Chen, Y. Therapeutic target database update 2022: facilitating drug discovery with enriched comparative data of targeted agents. *Nucleic Acids Res* **2022**, *50*, D1398-d1407, doi:10.1093/nar/gkab953.

30. Gupta, S.C.; Sung, B.; Prasad, S.; Webb, L.J.; Aggarwal, B.B. Cancer drug discovery by repurposing: teaching new tricks to old dogs. *Trends Pharmacol Sci* **2013**, *34*, 508-517, doi:10.1016/j.tips.2013.06.005.
31. Yuliwulandari, R.; Sachrowardi, Q.; Nakajima, H.; Kashiwase, K.; Hirayasu, K.; Mabuchi, A.; Sofro, A.S.M.; Tokunaga, K. Association of HLA-A, -B, and -DRB1 with pulmonary tuberculosis in western Javanese Indonesia. *Human Immunology* **2010**, *71*, 697-701, doi:https://doi.org/10.1016/j.humimm.2010.04.005.
32. Kone, A.; Diarra, B.; Cohen, K.; Diabate, S.; Kone, B.; Diakite, M.T.; Diarra, H.; Sanogo, M.; Togo, A.C.G.; Sarro, Y.D.S., et al. Differential HLA allele frequency in Mycobacterium africanum vs Mycobacterium tuberculosis in Mali. *Hla* **2019**, *93*, 24-31, doi:10.1111/tan.13448.
33. Leemans, J.C.; Florquin, S.; Heikens, M.; Pals, S.T.; van der Neut, R.; Van Der Poll, T. CD44 is a macrophage binding site for Mycobacterium tuberculosis that mediates macrophage recruitment and protective immunity against tuberculosis. *J Clin Invest* **2003**, *111*, 681-689, doi:10.1172/jci16936.
34. Riaz Khan, V.A., Sivasankar C., Deepa M. Hyaluronic Acid – TB Drug Conjugates for the Treatment of Active Tuberculosis Disease. *International journal of advanced Science and Engineering***, 2020**.
35. Thirumalaisamy, R.; Aroulmoji, V.; Iqbal, M.N.; Saride, S.; Bhuvaneswari, M.; Deepa, M.; Sivasankar, C.; Khan, R. Molecular insights of hyaluronic acid - ethambutol and hyaluronic acid - isoniazid drug conjugates act as promising novel drugs for the treatment of tuberculosis. *J Biomol Struct Dyn* **2022**, 10.1080/07391102.2022.2051748, 1-12, doi:10.1080/07391102.2022.2051748.
36. Gao, Y.; Sarfraz, M.K.; Clas, S.D.; Roa, W.; Löbenberg, R. Hyaluronic Acid-Tocopherol Succinate-Based Self-Assembling Micelles for Targeted Delivery of Rifampicin to Alveolar Macrophages. *J Biomed Nanotechnol* **2015**, *11*, 1312-1329, doi:10.1166/jbn.2015.2091.
37. Algood, H.M.; Flynn, J.L. CCR5-deficient mice control Mycobacterium tuberculosis infection despite increased pulmonary lymphocytic infiltration. *J Immunol* **2004**, *173*, 3287-3296, doi:10.4049/jimmunol.173.5.3287.
38. Das, S.; Banerjee, S.; Majumder, S.; Chowdhury, B.P.; Goswami, A.; Halder, K.; Chakraborty, U.; Pal, N.K.; Majumdar, S. Immune subversion by Mycobacterium tuberculosis through CCR5 mediated signaling: involvement of IL-10. *PLoS One* **2014**, *9*, e92477, doi:10.1371/journal.pone.0092477.
39. Hoshino, Y.; Tse, D.B.; Rochford, G.; Prabhakar, S.; Hoshino, S.; Chitkara, N.; Kuwabara, K.; Ching, E.; Raju, B.; Gold, J.A., et al. Mycobacterium tuberculosis-induced CXCR4 and chemokine expression leads to preferential X4 HIV-1 replication in human macrophages. *J Immunol* **2004**, *172*, 6251-6258, doi:10.4049/jimmunol.172.10.6251.
40. Senbagavalli, P.; Kumar, N.; Kaur, G.; Mehra, N.K.; Geetha, S.T.; Ramanathan, V.D. Major histocompatibility complex class III (C2, C4, factor B) and C3 gene variants in patients with pulmonary tuberculosis. *Hum Immunol* **2011**, *72*, 173-178, doi:10.1016/j.humimm.2010.11.002.
41. Wang, C.; Wei, L.L.; Shi, L.Y.; Pan, Z.F.; Yu, X.M.; Li, T.Y.; Liu, C.M.; Ping, Z.P.; Jiang, T.T.; Chen, Z.L., et al. Screening and identification of five serum proteins as novel potential biomarkers for cured pulmonary tuberculosis. *Sci Rep* **2015**, *5*, 15615, doi:10.1038/srep15615.
42. Finan, C.; Gaulton, A.; Kruger, F.A.; Lumbers, R.T.; Shah, T.; Engmann, J.; Galver, L.; Kelley, R.; Karlsson, A.; Santos, R. The druggable genome and

support for target identification and validation in drug development. *Science translational medicine* **2017**, *9*, eaag1166.